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Mycobacterium tuberculosis (M. tb) is able to persist within macrophages by utilizing its 
type VII ESX-1 protein secretion system to subvert host-defense mechanisms. ESX-1 is encoded 
by genes in two separate loci, the esx-1 locus and the espACD operon. EspD, encoded by the third 
gene on the espACD operon, had previously been found to be necessary within the mycobacterial 
cell for the stability and secretion of several ESX-1 proteins. However, the function of secreted 
EspD within the host-cell remains unknown. This question was addressed here through studies 
using M. tb strains expressing variant EspD proteins and through the characterization of 
recombinant EspD protein expressed and purified from Escherichia coli (E. coli). To generate 
these M. tb strains, an espA transposon insertion mutant (M. tb espA::Tn), which is unable to 
express the entire espACD operon, was used. M. tb espA::Tn was transformed with an empty 
plasmid vector (M. tb espA::Tn pMD31) or plasmid vectors encoding the espACD genes 
containing either wild-type espD (M. tb espA::Tn pMDespACDWT), espD containing a premature 
stop codon (M. tb espA::Tn pMDespACDSTOP), or espD containing single point mutations. While 
all strains exhibited similar growth rates, M. tb espA::Tn pMD31 and M. tb espA::Tn 
pMDespACDSTOP were deficient in both EsxA and EspD secretion. M. tb espA::Tn 
pMDespACDW19R was capable of secreting EsxA, but not EspD. All other strains expressing 
variants of EspD were able to secrete both EspD and EsxA to some level. During infections of 
THP-1 human macrophages, M. tb espA::Tn pMDespACDW19R appeared less cytotoxic and 
induced reduced production of the pro-inflammatory cytokines IL1 and TNF. These results 
strongly suggest that secreted EspD is involved in the induction of pro-inflammatory response. 
M. tb espA::Tn pMDespACDSTOP also appeared less cytotoxic to THP-1 cells, but in contrast 
induced an increased production of IL1 and TNF. This is a novel observation indicating that 
ESX-1 mediated cell death in macrophages does not necessarily correspond to an increased pro-
inflammatory response. Additionally, purified recombinant EspD appears to be capable of 
forming a large oligomeric structure and appears to bind specifically to several eukaryotic 
phospholipids, including PI4P. It is unknown if this binding occurs in vivo or if this binding 
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1.1. Tuberculosis  
Tuberculosis (TB) is a severe chronic infection that has plagued the human population for 
millennia and is currently estimated to affect one quarter of the world’s population (World Health 
Organization, 2019). In 2019, 1.4 million lives were claimed by this disease with over 200,000 
deaths as a result of co-infections with human immunodeficiency virus (HIV) (World Health 
Organization, 2019). TB is the number one cause of death due to a single bacterial pathogen, the 
bacillus Mycobacterium tuberculosis (M. tb) (Philips and Ernst, 2012). Infections with M. tb most 
commonly affect the lungs (pulmonary TB), but can impact other organs as well (extrapulmonary 
TB) if dissemination has occurred (Pai et al., 2016). In Canada, overall case numbers of TB have 
been declining since the middle of the 20th century, but the remaining cases disproportionately 
affect Aboriginal and foreign-born Canadians (Public Health Agency of Canada, 2014). TB 
remains a major global and local health problem and further research and innovation are critical 
to further understand, prevent, and treat TB in order to end this epidemic.  
There are three potential outcomes of an exposure to M. tb. Firstly, the host may be able 
to successfully eliminate the bacteria (Ernst, 2012). This can occur due to acquired T-cell 
immunity or due to an effective innate immune response that clears the pathogen from the body 
entirely (Pai et al., 2016). In the second possible outcome of an M. tb exposure, the host will not 
eliminate the pathogen, but instead remain latently infected (World Health Organization, 2019). 
The individual will exhibit a persistent immune response to M. tb to control the infection, but 
will remain asymptomatic (World Health Organization, 2019). Around 10% of latently infected 
people are likely to reactivate and progress into active disease in their lifetime, which is the third 
possible outcome of M. tb exposure (Pai et al., 2016). Symptoms of Active TB include coughing, 
fever, weight loss, hemoptysis, and could result in death if the disease goes untreated (Public 
Health Agency of Canada, 2014). Those infected with HIV are much more likely to develop TB 
disease (Pai et al., 2016). Similarly, individuals experiencing undernutrition, diabetes, alcoholism, 
or those who smoke have a higher probability for progression to active disease following an 






1.1.1 Mycobacterium tuberculosis complex 
M. tb is the primary causative agent of TB and has no reservoir in the environment outside 
of humans (Pai et al., 2016). In addition to M. tb there are several other pathogenic mycobacteria 
that are capable of causing TB disease across several species, these mycobacteria are collectively 
named the Mycobacterium tuberculosis complex (MTBC) (Forrellad et al., 2013). The MTBC 
includes M. tb, Mycobacterium africanum, Mycobacterium bovis (M. bovis), Mycobacterium 
caprae, Mycobacterium canettii, Mycobacterium microti, and Mycobacterium pinnipedii. These 
species are genetically very similar and taken together can infect a wide range of animals 
(Forrellad et al., 2013). A very small fraction of human TB cases are known to be caused by 
infections with Mycobacterium africanum, M. bovis, or Mycobacterium caprae (Pai et al., 2016). 
M. bovis is also capable of infecting animals associated with agriculture, like cattle. The resulting 
bovine TB disease leads to significant economic loss around the world (Ejeh et al., 2014; Pérez-
Morote et al., 2020).  
 
1.1.2. Treatment and prevention of TB 
Recommended treatment of TB involves a six-to-nine-month chemotherapy regimen 
involving a combination of several anti-microbial drugs (Pai et al., 2016). The first-line drugs 
used to treat TB are isoniazid, rifampin, ethambutol, and pyrazinamide (World Health 
Organization, 2019). A typical drug regimen would include taking all four first-line drugs daily 
for two months followed by an additional four months taking just isoniazid and rifampin (Pai et 
al., 2016). Treatment can be very difficult to complete as it requires vigilance from the patient 
and can cause several uncomfortable side-effects (World Health Organization, 2019). These 
challenges contribute to the increasing number of drug-resistant TB cases. Globally, more than 
3% of new TB cases and around 18% of previously treated cases were found to be multidrug-
resistant (World Health Organization, 2019). Success in treating these cases is becoming 
increasingly more difficult to achieve and indicates the necessity for more effective treatments 
and vaccines to prevent infection.  
The only vaccine currently available against TB is a live-attenuated strain of M. bovis 
called bacillus Calmette Guérin (BCG) (Philips and Ernst, 2012). Routine vaccination with BCG 
is widely performed around the world and has been very successful in preventing severe forms 
of TB in young children (World Health Organization, 2019). BCG was developed through serial 
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passaging of M. bovis over the course of 13 years, from 1908-1921, now making it 100 years old 
(Tran et al., 2014). Passaging allowed for spontaneous genetic deletions to occur, leading to the 
attenuation observed in BCG (Tran et al., 2014). Despite being very safe and effective in infants, 
the vaccine is considered controversial as its efficacy is highly variable (0-80%) (Anderson and 
Doherty, 2005). In Canada, BCG vaccination is only recommended for some travellers and young 
children in settings with high-incidences of TB (Public Health Agency of Canada, 2014). 
Efficacy of the BCG vaccine often wanes once the individual reaches adolescence (Pai et al., 
2016). To this point, there is no reliable vaccine against TB for adults.  
 
1.2. M. tb pathogenesis 
M. tb is a slow-growing, facultative intracellular pathogen with a low infective dose (<10 
bacilli) and is easily spread through aerosol droplets (Pai et al., 2016). After being breathed in by 
the host, the bacterium enters the lower respiratory tract and eventually reaches the lung alveoli 
(Lerner et al., 2015). Resident phagocytes including alveolar macrophages, dendritic cells, and 
neutrophils make up the innate defense against M. tb in this region (Lerner et al., 2015). 
Macrophages are the first host-cell to encounter and phagocytose M. tb after an exposure (Liu et 
al., 2017a). Cells that effectively neutralize and eliminate the bacteria will prevent an infection 
from being established (Pai et al., 2016). Macrophages have several methods of defense including 
phagosome acidification, autophagy, nitrosative and oxidative stresses, cytokine production, and 
more (Sia and Rengarajan, 2019). If macrophages are unable to eliminate M. tb, they become the 
primary niche for the bacteria to replicate and survive (Sia and Rengarajan, 2019). M. tb has 
developed strategies to hijack key host-cell defense mechanisms allowing it to persist within the 
host for long periods of time, often in a state of latency (Stutz et al., 2018). M. tb is able to evade 
the acidification of the phagosome and can adapt to the immunological pressures of the 
intracellular environment using highly specialized virulence factors (Sia and Rengarajan, 2019). 
 
1.2.1. Phagosomal maturation 
Macrophages express pattern recognition receptors on their surface that recognize 
invading microorganisms through the pathogen-associated molecular patterns (PAMPs) on the 
bacterial surface (Xu et al., 2014). This recognition begins a signalling cascade that readies the 
macrophage’s host-cell defence mechanisms (Xu et al., 2014). Phagocytosed material is then 
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contained within the host-cell in a membrane-bound structure called a phagosome (Stutz et al., 
2018). The phagosome then proceeds through a process called phagosomal maturation wherein 
the engulfed material is inactivated after stepwise fusion processes with endosomes and 
lysosomes (Figure 1) (Poirier and Av-Gay, 2012). The final fusion step with the lysosome gives 
rise to the phagolysosome. This compartment will have a lower internal pH, and reactive oxygen 




Figure 1: Phagosomal maturation is the process by which a phagosome containing engulfed 
foreign material is fused with endosomes and lysosomes in order to inactivate the internalized 
material. M. tb is able to inhibit phagosomal maturation. Figure is adapted from Poirier and Av-
Gay, 2012.   
 
M. tb is an ancient bacterium that has been co-evolving alongside its human host for a 
very long time (Zhang et al., 2021). This has allowed M. tb to develop successful strategies to 
avoid being killed within the host macrophage in several ways (Liu et al., 2017a). M. tb can 
inhibit phagosomal maturation, hijack the phagosome to be an intracellular habitat, and cause 
damage to the phagosomal membrane to allow for escape into the cytosol (Stutz et al., 2018). 
There are several M. tb virulence factors that have been demonstrated to be involved in these 
processes. For example, SapM is a secreted 3-phosphatase that functions on phosphatidylinositol 
3-phosphate (PI3P) to produce phosphatidylinositol (PI), ultimately inhibiting phagosomal 
maturation by blocking the fusion between the lysosome and the phagosome (Puri et al., 2013). 
The presence of PI3P on phagosomes is linked to maturation of the phagosome and can be 
observed in higher concentrations when macrophages are infected with attenuated mycobacteria 
as opposed to virulent strains (Vergne et al., 2005). Lower levels of PI3P on the phagosome are 
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proposed to stop the binding of early endosomal markers such as early endosome antigen-1 
(EEA1) and hepatocyte growth factor–regulated tyrosine kinase substrate (Hrs), which possess 
PI3P binding domains (Hu et al., 2015; Vieira et al., 2001).  
M. tb has also demonstrated the ability to escape from the phagosome entirely and enter 
the cytosol of the host-cell (Zhai et al., 2019). This process is dependent on one of M. tb’s Type 
VII secretion systems, ESX-1 (Sia and Rengarajan, 2019). It was originally proposed that a 
prominent secreted effector of this system, the 6 kDa early secretory antigen target (ESAT-6), 
also called EsxA, may be capable of lysing membranes and destabilizing the phagosome by 
creating pores (De Jonge et al., 2007). Recent work has demonstrated that the ESX-1 dependent 
lysis may be due to direct contact between the bacterium and the eukaryotic membrane, which 
leads to tearing of the phagosome (Conrad et al., 2017). 
 
1.2.2. Autophagy 
 Autophagy is a programmed pathway in eukaryotic cells that allows for the turnover of 
degraded material in the cytoplasm (Deretic, 2008). These turnover processes can also be 
involved in the innate and adaptive immune responses necessary to control intracellular 
pathogens (Gutierrez et al., 2004). Autophagy is important for regulating the major 
histocompatibility complex (MHC) class II presentation of antigens from these internalized 
pathogens (Romao et al., 2013). M. tb has demonstrated an ability to suppress antigen 
presentation during infections (Saini et al., 2016). The virulence protein PE_PGRS47 was found 
to be critical in the inhibition of autophagy and antigen presentation that occurs during M. tb 
infections of macrophages (Saini et al., 2016).  
The foreign material destined for degradation through autophagy is surrounded by a 
double membrane and contained within a structure called the autophagosome (Romao et al., 
2013). Similar to phagosomal maturation, this structure requires maturation and acidification 
through fusion with the lysosome (Harris et al., 2017). The autophagosomal membrane becomes 
decorated with PI3P, which recruits EEA1 and Hrs to perform organelle tethering and membrane 
sorting functions required for lysosomal fusion (Deretic, 2008). Virulent M. tb strains have 
demonstrated an ability to avoid being killed through this autophagic process, by inhibiting the 
late stage of autophagy in an ESX-1-dependent manner (Romagnoli et al., 2012). The inhibition 
of these bacteriolytic processes in the host cell facilitate the opportunity for M. tb to escape into 
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the cytosol and replicate (Pai et al., 2016). Ultimately, the macrophage will be killed, enabling 
the bacteria to infect other cells (Di Russo Case and Samuel, 2016). 
 
1.2.3. TB induced host-cell death pathways 
 The death of macrophages and subsequent release of the infecting M. tb bacteria is an 
important step in the pathogenesis of TB disease (Pai et al., 2016). Despite that there is little 
known about the mechanism of how M. tb infected macrophages decide to perform programmed 
cell death, this death has been demonstrated to involve rupture of cell membranes, permeability 
of the mitochondria and lysosome, and the production of ROS (Lee et al., 2011; Zhao et al., 
2017). There are several identified pathways of programmed cell death that have been identified 
during M. tb’s killing of macrophages. These include apoptosis, which is the most well described 
method of programmed cell death, as well as necroptosis and pyroptosis, which are programmed 
forms of necrosis (Zhang et al., 2021). 
 Apoptosis is a form of cell death that is necessary for normal development in host 
organisms, but it can also be involved in the immune response against infecting pathogens (Zhang 
et al., 2021). Several hallmarks of apoptotic cell death include shrinking of the cell, membrane 
blebbing, exposure of phosphatidylserine (PS) on the outer surface of the cell, and the formation 
of apoptotic bodies (Nagata, 2018). In the case of M. tb infected macrophages, apoptosis has been 
reportedly induced in association with either autocrine or paracrine signaling of a key pro-
inflammatory cytokine, tumor necrosis factor α (TNFα) (Keane et al., 1997). Notably, virulent 
strains of M. tb lead to less apoptosis of infected cells than is observed with avirulent strains 
(Keane et al., 2000). Extending the life of an infected host-cell can be beneficial to the pathogen 
as it can continue to replicate within the intracellular environment, therefore M. tb’s ability to 
suppress apoptosis in macrophages contributes to its ability to persist within the host (Di Russo 
Case and Samuel, 2016). 
 While macrophages infected with attenuated strains of M. tb predominantly die through 
apoptosis, virulent strains of M. tb induce macrophage necrosis (Divangahi et al., 2009). However, 
it is not fully clear how much of this M. tb induced necrosis is ‘accidental’ and how much is 
specifically driven by the macrophage. Necroptosis is defined as an inflammatory cell death that 
is a type of programmed necrosis (Berghe et al., 2014). Similarly to apoptosis, necroptosis is 
associated with the stimulation of TNFα production, which at high levels can lead to 
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mitochondrial ROS production (Xu et al., 2014). There is still much to be understood about how 
necroptosis is involved in M. tb induced cell death, but it appears to be favoured by virulent M. 
tb strains as it allows for survival and spread of the bacteria (Zhang et al., 2021). 
Another form of programmed necrosis is pyroptosis, which has been demonstrated to 
involve the activation of inflammasome complexes (Zhang et al., 2021). Inflammasomes are 
eukaryotic protein complexes that function to activate caspases that directly contribute to the 
inflammatory response (Broz and Dixit, 2016). Inflammasome complexes are formed as a host-
defense response when pathogens are detected within immune cells (Rathinam and Fitzgerald, 
2016). M. tb has been implicated in manipulating both the absent in melanoma 2 (AIM2) and 
NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome complexes in 
infected macrophages (Mishra et al., 2010; Shah et al., 2013). The AIM2 inflammasome is 
constructed when the inflammatory ligand AIM2 binds to the adapter protein apoptosis-
associated speck-like protein containing a CARD domain (ASC) which further binds the 
inflammatory caspase, caspase-1 (Figure 2a) (Schroder and Tschopp, 2010). Oligomerization of 
these components then forms the AIM2 inflammasome which auto-processes caspase-1 into the 
active form of cleaved caspase-1 which can then cleave Pro-interleukin-1 ß (IL1ß) into IL1ß 
(Broz and Dixit, 2016). It has been proposed that virulent M. tb is able to inhibit the AIM2 
inflammasome, which allows the bacterium to control IL1ß production (Shah et al., 2013). 
However, details of how this inhibition occurs are yet to be understood. 
 
Figure 2: Unoligomerized inflammasome complexes for the (a) AIM2 and (b) NLRP3 
inflammasomes. Figure adapted from Schroder and Tschopp, 2010.  
 
Similarly to the AIM2 inflammasome, the NLRP3 inflammasome involves complexing 
of ASC and caspase-1 (Swanson et al., 2019). This inflammasome is constructed on the Golgi 
apparatus after NLRP3 is recruited and scaffolded to phosphatidylinositol 4-phosphate (PI4P), 
which makes up a significant portion of the Golgi apparatus (Chen et al., 2019). NLRP3 is then 
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able to bind ASC and caspase-1, oligomerize, and form the NLRP3 inflammasome complex 
(Figure 3) (Chen et al., 2019). Cleaved caspase-1 can then cleave pro-IL1ß into IL1ß, 
contributing to the pro-inflammatory response (Yang et al., 2019). M. tb has been shown to 
induce IL1ß production through activation of the NLRP3 inflammasome in macrophages in an 
ESX-1 dependent fashion (Dorhoi et al., 2012). The secreted effector EsxA has been proposed 
to be responsible for this NLRP3 activation, as M. tb ΔesxA was only capable of low levels of 
IL1ß production in macrophages (Mishra et al., 2010). 
 
 
Figure 3: Negatively charged PI4P on the dispersed trans-golgi network recruits NLRP3 through 
ionic bonding with its poly-lysine motif. NLRP3 aggregates and further binds to ASC for 
formation of the inflammasome. Figure adapted from Chen et al., 2019.  
 
1.3. Type VII secretion systems 
M. tb possesses five distinct ESX secretion systems, at least three of which (ESX-1, ESX-
3, and ESX-5), appear to be necessary for the bacteria’s viability or virulence (Figure 4) (Bottai 
et al., 2017). These specialized Type VII secretion systems are required to transport substrates 
across the thick and mycolic acid-rich cell envelope, which provides protection to the bacterium 
when exposed to harsh environmental conditions (Gröschel et al., 2016). The five ESX systems 
of M. tb differ in their genetic size and complexity, but they all share several core features. Firstly, 
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each of the ESX loci contain a pair of esx genes (esxA and esxB in ESX-1), which encode for 
small proteins with a Tryptophan-X-Glycine (WXG) motif (Gröschel et al., 2016). Secondly, 
these systems encode esx conserved component (ecc) genes, which express the proteins important 
for the mechanistic components of a secretion system (Bottai et al., 2017). These proteins contain 
ATP-binding and transmembrane domains (Bottai et al., 2017). Next, all systems contain a mycP 
gene, which encodes a subtilisin-like serine protease (Chen, 2016). Lastly, all systems excluding 
ESX-4 contain pe and ppe genes, which encode proteins with Proline-Glutamate (PE) and 
Proline-Proline-Glutamate (PPE) motifs their N-terminal regions (Bottai et al., 2017). These 
proteins represent two mycobacteria-specific classes of proteins, members of which have been 
implicated in variety of functions including intracellular growth, phagocytosis, phagosomal 




Figure 4: Genetic organization of the ESX secretion systems of M. tb. The espACD operon is 
located 300 kb upstream of the esx-1 locus. The region identified as the ΔRD1 region indicates 
the genes lost in the M. bovis BCG vaccine strain that interrupts the ESX-1 system, contributing 
to its attenuation. The absent RD1 region includes the gene for EsxA, the most highly 
characterized ESX effector. Image adapted from Groschel et al., 2016. 
 
 10 
Of the M. tb Type VII secretion systems, ESX-4 is the simplest. It is composed of the 
least number of genes and is thought to be an ancestral system through which the other ESX 
systems may have evolved (Bottai et al., 2017). ESX-4, along with ESX-2, appears to be a non-
essential system that is uninvolved in M. tb’s intracellular survival or virulence (Gröschel et al., 
2016). The functions of both ESX-4 and ESX-2 are entirely unknown (Bunduc et al., 2020).  
ESX-3 is highly conserved across different mycobacterial species and is predominantly 
established to be involved in metal acquisition and homeostasis (Gröschel et al., 2016). A pair of 
secreted proteins, the EsxG-EsxH heterodimer of the ESX-3 system, are implicated as regulators 
for the secretion of several proteins of the PE and PPE protein families (Tufariello et al., 2016). 
This system has also been found to be involved in M. tb virulence, as depending on the genotype 
of the host, the ESX-3 system is capable of counteracting a restricted iron availability (Bottai et 
al., 2017). Additionally, the EsxG-EsxH complex is known to impair phagosomal maturation in 
M. tb infected macrophages through EsxH interaction with the host’s Hrs protein (Mehra et al., 
2013). Hrs is a eukaryotic protein that contributes to sorting processes directing material for 
lysosomal degradation (Mehra et al., 2013). 
ESX-5 is evolutionarily the most recently emerged of the ESX systems (Bunduc et al., 
2020). Unlike ESX-3, ESX-5 is only present in slow-growing species of mycobacteria (Bottai et 
al., 2017). This system is proposed to be necessary for bacterial viability due to its role in nutrient 
uptake (Bunduc et al., 2020). Additionally, ESX-5 exports many PE and PPE proteins, which are 
largely encoded on entirely distinct loci from the genes encoding the ESX-5 system itself 
(Gröschel et al., 2016). Loss of ESX-5 secretion leads to considerable damage to the cell envelope 
of the mycobacteria (Bottai et al., 2012). 
 
1.3.1. The ESX-1 system 
Much of M. tb’s ability to survive within macrophages is due to the ESX-1 system. As 
mentioned, this system is involved in avoiding phagosomal maturation (Stutz et al., 2018) and 
autophagy (Romagnoli et al., 2012), preventing apoptosis (Keane et al., 2000) and inducing 
necrosis (Wong and Jacobs, 2011) as well as activating the NLRP3 inflammasome (Dorhoi et al., 
2012). Yet, much is still to be elucidated about this system. Very few structures have been 
obtained for the mechanistic components of ESX-1 and the actual mechanism of secretion is still 
largely unknown (Figure 5) (Bottai et al., 2017). Type I, Type III, and Type VI secretion occur 
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through a channel that spans both membranes of a Gram-negative bacterium, allowing substrates 
to be secreted in a single step. Type II and Type IV secretion systems work together with the 
SecA-dependent or Twin-arginine translocation (TAT) cytoplasmic membrane transport systems 
to secrete substrates (Beeckman and Vanrompay, 2010). With Type VII, the Ecc core components 
contain transmembrane domains, which could span across the mycomembrane, and the ESX 
substrates do not encode for Sec or TAT signal sequences, therefore it has been hypothesized that 
this secretion could also occur in a single step (Houben et al., 2012).  
 
 
Figure 5: Organization of the components of the ESX-1 Type VII secretion system of M. tb. 
 
1.3.2. ESX-1 secreted proteins 
M. tb’s ESX-1 system is encoded by 23 genes spanning two separate loci on the bacterial 
chromosome, the esx-1 locus and the esx-1 secretion-associated proteins ACD (espACD) operon 
(Figure 4) (Gröschel et al., 2016). Several of these genes, namely those called esp or esx genes, 
encode for proteins thought to be secreted themselves or somehow involved in secretion 
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modulation (Gröschel et al., 2016). Secreted proteins are some of the main tools M. tb uses during 
infection to survive intracellularly and hijack host-cell defence mechanisms. EsxA, EsxB, EspA, 
EspB, EspC, and EspD have all been identified as secreted proteins of the ESX-1 system (Bottai 
et al., 2017). 
The most well characterized member of the ESX-1 system is EsxA, which is a 6 kDa 
secreted effector known to be a potent T-cell antigen (Aguiló et al., 2013). EsxA is co-secreted 
as a heterodimer with another effector, EsxB, also called 10 kDa culture filtrate protein, (CFP-
10) (Fortune et al., 2005). EsxA is linked to M. tb’s ability to disrupt the phagosome during 
macrophage infections (De Jonge et al., 2007). The ability of EsxA to form pores in the 
phagosomal membrane through lytic activity is controversial, however EsxA remains an essential 
component of M. tb’s virulence. EsxA is also thought to induce NLRP3 inflammasome activation 
in macrophages contributing to the pro-inflammatory response (Mishra et al., 2010). 
Another core member of the ESX-1 system that is necessary for the full virulence of M. 
tb is EspB. EspB is expressed as a 60 kDa protein, processed by the MycP1 protease, and secreted 
as a 50 kDa substrate (Ohol et al., 2010). The secretion of EspB does not require co-secretion 
with EsxA or EsxB and does not require the expression of the products of the espACD operon 
(Chen et al., 2013a). Recombinant EspB purified from Escherichia coli (E. coli) has been shown 
to inhibit IFN-γ-induced autophagy in murine macrophages (Huang and Bao, 2016). Additionally, 
EspB may contribute to M. tb’s virulence through binding of the eukaryotic phospholipids 
phosphatidic acid (PA) and PS (Chen et al., 2013a).  
 
1.3.3. The espACD operon 
 The espACD operon is located around 300 kb upstream of the esx-1 locus in the genomes 
of pathogenic mycobacteria (Bottai et al., 2017). The genes of this operon are all co-transcribed 
and are regulated by the DNA-binding protein EspR (Blasco et al., 2012; Chen et al., 2012). The 
EspA, EspC, and EspD proteins are homologous to the core esx-1 proteins EspE, EspF, and EspH, 
respectively (Gröschel et al., 2016). EspA and EspC are also co-secreted with EsxA and EsxB 
through the ESX-1 system (Fortune et al., 2005). EspA requires both EspC and EspD to be 
expressed in order to maintain normal protein levels within the mycobacterial cell. Similarly, for 
EspC to remain stable and for EspA and EspC to be secreted, EspD needs to be present within 
the mycobacterium (Chen et al., 2012). Despite being critical for the secretion of EsxA and EsxB, 
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EspA’s function as a secreted protein has yet to be fully understood (Chen et al., 2013b). EspC 
has been found to be able to form long filamentous oligomers and recently has been implicated 
in the induction of endoplasmic reticulum stress-mediated apoptosis (Guo et al., 2021; Lou et al., 
2017). 
 
1.3.4. Published data on EspD 
To date, the work done to establish the function of EspD has taken a genetic approach, 
using mutated M. tb strains and determining the impact of these mutations on the function of the 
mycobacteria. A transposon insertion into the espA gene stops the expression of EspA, EspC, and 
EspD and therefore creates a strain missing the entire espACD operon, called M. tb espA::Tn. 
This disruption attenuates the bacteria and is known to significantly decrease its relative 
cytotoxicity during infections (Chen et al., 2013). However, this strain can further be 
complemented with a plasmid encoding the entire espACD operon or a plasmid encoding the 
espACD operon containing targeted truncations, single point mutations, or early stop codons in 
order to express variants of EspD within M. tb. These strains are called M. tb espA::Tn pMD31 
(empty vector, missing the espACD operon), M. tb espA::Tn pMDespACDWT (fully 
complemented wildtype strain), and M. tb espA::Tn pMDespACDSTOP (early stop codon in espD 
prevents expression of EspD alone). Using these strains, as well as strains encoding single point 
mutations on EspD, the functions of EspD within the mycobacterial cell were defined. EspD 
maintains the stability of EspA and EspC and facilitates the secretion of EspA, EspC, EsxA, and 
EsxB (Chen et al., 2012). EspD itself however, was found to still be capable of secretion when 
all other ESX-1 secretion is shut down (Chen et al., 2012). Additionally, EspD has been identified 
as a binding partner to another ESX-1 component, EspL, but little is known about the 
consequences of this interaction (Sala et al., 2018). There is no published work on the function 
of secreted EspD protein. It is currently unknown what impact EspD secretion has on the 
eukaryotic host-cell during M. tb infection.  
 
1.3.5. Unpublished work on EspD characterization 
Previous work established the secretion profile for an M. tb strain expressing EspD with 
a Tryptophan to Arginine mutation on position 19 (W19R), M. tb espA::Tn pMDespACDW19R. 
This strain is deficient in EspDW19R secretion alone and is still capable of secreting other ESX-1 
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members (Chen et al., 2012). M. tb espA::Tn pMDespACDW19R was tested alongside M. tb 
espA::Tn pMDespACDWT and M. tb espA::Tn pMDespACDSTOP to observe any differences in 
the bacterial load present in the lungs and spleen of infected mice after 14-days (Figure 6). This 
experiment indicated a significant reduction in the bacterial load in mice infected with M. tb 
espA::Tn pMDespACDW19R compared to M. tb espA::Tn pMDespACDWT. This data appears to 
indicate that secreted EspD protein contributes to M. tb virulence.  
 
 
Figure 6: Bacterial load measured in (a) lung and (b) spleen of mice infected with M. tb espA::Tn 
pMDespACDSTOP, M. tb espA::Tn pMDespACDWT and M. tb espA::Tn pMDespACDW19R for 14 
days. (*) indicates a statistically significant difference with p < 0.05.  
 
To begin investigating the role of secreted EspD, attempts were made to express the 
protein in E. coli for purification. Gene products from M. tb are notoriously difficult to express 
and purify from E. coli due to a lack of necessary chaperones and the high GC content of 
mycobacterial genes (Miyoshi-Akiyam et al., 2012). Due to these challenges, the attempt to 
express and purify EspD resulted in only very limited amounts of the protein. Nevertheless, some 
analyses of EspD protein’s structure and function were conducted.  
Recombinant EspD protein was subjected to size exclusion chromatography (SEC) and 
transmission electron microscopy (TEM) to analyze any quaternary structure of the protein. 
EspD’s size was observed through SEC on an S-400 sephacryl column by monitoring the A280 
nm as protein was eluted. EspD appeared to demonstrate structures upwards of 400 kDa in size 
across various salt concentrations, with a slight increase in oligomer size in higher salt 
concentrations (Figure 7a). This oligomerization was further investigated with TEM at 100k 
magnification of the recombinant protein sample. The EspD protein appeared to be forming 
oligomers representative of a ball-on-chain structure, which appeared to be of various sizes 
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(Figure 7b). Taken together, this data appears to indicate that EspD binds to itself to form large 
scale oligomers.   
 
 
Figure 7: (a) SEC performed on S-400 sephacryl column using natively purified EspD in a series 
of buffers containing a variety of salt concentrations. (b) TEM image of recombinant EspD 
sample taken at 100k magnification. Yellow arrows indicate some of the protein appearing to 
form oligomeric structures. 
 
 Attempts to determine a biochemical function for EspD were additionally explored. 
Purified recombinant EspD protein did not appear to be toxic to cells in culture and was not found 
to exhibit any enzymatic function (data not shown). Another M. tb secreted protein, EspB, is 
known to interact with the eukaryotic phospholipids, PA and PS (Chen et al., 2013a). Therefore, 
EspD was examined for a similar ability using membranes embedded with a variety of eukaryotic 
phospholipids. Binding was observed through immunoblot. EspD appeared to bind specifically 
to several phospholipids, namely, the phosphatidylinositol monophosphates, PA, and PS (Figure 
8). These molecules are involved in a variety of key processes within the cell and are commonly 
targeted by effectors of bacterial pathogens to promote bacterial survival during infections (Ham 
et al., 2011; Walpole et al., 2018; Yeung et al., 2009). EspD-phospholipid binding could aid M. 
tb during infection in its ability to survive and persist within a host by disrupting normal host-




Figure 8: Phospholipid embedded (a) Membrane Lipid Strip and (b) PIP Array were incubated 
with the sample of recombinant EspD protein. Signal was detected through immunoblot with α-























2. Rationale, Hypothesis, and Objectives 
2.1. Rationale  
The M. tb secreted protein EspD has demonstrated its importance within the 
mycobacterial cell to facilitate the secretion and maintain the stability of several ESX-1 members 
(Chen et al., 2012). EspD was also shown to be secreted when all other ESX-1 secretion appears 
to have been shut down (Chen et al., 2012). This result implies that EspD secretion may be a 
priority to the bacteria. Therefore, the role of secreted EspD is of interest for investigation. 
Unpublished work on purified recombinant EspD has demonstrated that the protein may be 
involved in binding eukaryotic phospholipids. Bacterial effectors capable of binding host-cell 
phospholipids can disrupt normal microbicidal functions such as phagosomal maturation and 
autophagy, ultimately contributing to bacterial survival and virulence (Ham et al., 2011; Walpole 
et al., 2018; Yeung et al., 2009). Using a combination of genetic and biochemical approaches, 
we seek to understand the role of secreted EspD during M. tb infections of macrophages.  
 
2.2. Hypothesis 
 Secreted EspD interacts with eukaryotic phospholipids and disrupts host-cell processes to 
potentiate ESX-1 mediated M. tb virulence.  
 
2.3. Objectives 
To investigate this hypothesis, three main objectives were established: 
 1. Characterization of M. tb strains that express variants of EspD. The construction and 
characterization of these M. tb strains allows us to observe phenotypic differences caused by 
these point mutations through comparison with M. tb expressing wild-type EspD. Strains will be 
monitored for their relative growth rates, secretion profiles, and cytotoxicity in macrophages.  
2. Analysis of the impact of secreted EspD during M. tb infections of human macrophages. 
Macrophages infected with M. tb strains that express variants of EspD will be examined for the 
impact of secreted EspD on cytokine production, inflammatory pathway activation, and 
phospholipid organization.  
3. Purification of recombinant EspD protein from E. coli to investigate the structure and 
function of secreted EspD. Recombinant protein will be evaluated for its ability to form oligomers 
and bind phospholipids.  
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3. Materials and Methods  
All chemicals were reagent grade and obtained from Sigma-Aldrich (St. Louis, MO) 
unless otherwise noted. All experiments involving M. tb bacteria were performed in a biosafety 
level (BSL) 3 laboratory. Samples transferred from BSL-3 to BSL-2 were filtered to remove 
bacteria. 
 
3.1. M. tb espA::Tn variant strain construction  
3.1.1. pMDespACD plasmid collection  
Previous lab members cloned the entire espACD operon sequence from M. tb into the 
episomal E.coli-mycobacteria shuttle vector, pMD31 (sourced from the Liu lab at University of 
Toronto), containing a kanamycin resistance cassette. This construct was named pMDespACD. 
Several single point mutations were performed to the espD gene region of pMDespACD and the 
resultant plasmids were inherited for this thesis and are detailed below.  
 
3.1.2. Transformations into M. tb espA::Tn  
M. tb espA::Tn strain was sourced from the Stewart Cole lab at École polytechnique 
fédérale de Lausanne (Lausanne, Switzerland). Middlebrook 7H11 Agar Base, Middlebrook oleic 
acid-albumin-dextrose-catalase (OADC) Growth Supplement, and Middlebrook 7H9 Broth Base 
were purchased from Becton, Dickinson and Company (Franklin Lakes, NJ) and prepared 
according to manufacturer’s instructions. M. tb espA::Tn cultures were grown in Middlebrook 
7H9 liquid media to mid-late log phase of growth. Bacteria was pelleted by centrifugation at 3000 
x g for 5 min. Supernatants were discarded and the volume was replaced with 10% glycerol to 
resuspended the bacterial pellet, followed by pelleting at 3000 x g for 5 mins. This was repeated 
three additional times, decreasing the volume of 10% glycerol solution by half each time. The 
final pellet was resuspended in 1/10th the original volume of culture in 10% glycerol. Competent 
M. tb espA::Tn cells were combined with purified pMD31, pMDespACD, or a mutated 
pMDespACD plasmid sample in an electroporation cuvette and allowed to incubate at room 
temperature (RT) for 10 min prior to electroporating at 2.5 kV using the Bio-Rad Gene Pulser 
Xcell Microbial System. Gene Pulser electroporation cuvettes (0.2 cm gap) were purchased from 
Bio-Rad Laboratories (Hercules, CA). Cells were added to Middlebrook 7H9 media and allowed 
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to recover at 37°C with 100 rpm shaking for 24 h. Recovered bacteria was plated on Middlebrook 
7H11 agar and allowed to incubate at 37°C until colonies appear.  
 
Table 1: List of all M. tb espA::Tn strains transformed with variants of pMD31 or pMDespACD 
vectors.  
Strain name Variation 
M. tb espA::Tn pMD31 Missing the genes that encode for EspA, EspC, and EspD 
M. tb espA::Tn pMDespACDWT Fully complemented, wild-type strain 
M. tb espA::Tn pMDespACDSTOP Gene that encodes for EspD has a premature stop codon, 
resulting in lack of EspD protein 
M. tb espA::Tn pMDespACDW19R Expresses EspD with W19R mutation, EspDW19R 
M. tb espA::Tn pMDespACDW27R Expresses EspD with W27R mutation, EspDW27R 
M. tb espA::Tn pMDespACDP31A Expresses EspD with P31A mutation, EspDP31A 
M. tb espA::Tn pMDespACDR83A Expresses EspD with R83A mutation, EspDR83A 
M. tb espA::Tn pMDespACDR92A Expresses EspD with R92A mutation, EspDR92A 
M. tb espA::Tn pMDespACDR113A Expresses EspD with R113A mutation, EspDR113A 
M. tb espA::Tn pMDespACDK115A Expresses EspD with K115A mutation, EspDK115A 
M. tb espA::Tn pMDespACDR169A Expresses EspD with R169A mutation, EspDR169A 
 
3.2. M. tb espA::Tn strain tests  
All M. tb espA::Tn strains containing pMD vectors (Table 1) were streaked onto 
Middlebrook 7H11 + 10% Middlebrook OADC + 30 /mL kanamycin selective agar and grown 
at 37°C for several weeks until colonies form. Single colonies were resuspended in 7H9 complete 
media (Middlebrook 7H9 + 10% ADC broth + 0.05% Tween-80 + 30 μg/mL kanamycin) and 
grown for several days to the desired optical density (OD600) at 37°C with 100 rpm shaking. 
These cultures grown in 7H9 complete media inoculated with colonies from 7H11 agar are hereby 
called starter cultures.   
 
3.2.1. Growth curves 
Starter cultures were shifted into either 7H9 complete media or Sautons media (0.06% 
glycerol, 4 g/L L-Asparagine, 2 g/L Citric Acid, 0.5 g/L KH2PO4, 0.5 g/L MgSO4 · 7H2O, 0.05 
g/L Ammonium iron (III) citrate, 0.1 mL/L ZnSO4 · H2O, pH 7.4) + 0.05% Tween-80 at a starting 
OD600 of 0.1. Cultures were grown for 48 h intervals at 37°C with 100 rpm shaking undisturbed. 
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At each interval, OD600 was measured after thorough culture resuspension and centrifugation at 
300 x g for 2 min. Cultures were diluted in inactivating diluent of phosphate buffered saline (PBS) 
+ 5% formaldehyde + 0.05% Tween-20 to measure the OD600 in biological duplicates using 
SpectraMax i3x with SoftMax Pro version 7.0.3 Data Acquisition and Analysis software. The 
measure of a blank (media diluted in inactivating diluent) was subtracted from measurements of 
the diluted cultures. Final values were calculated from averaging duplicates, after adjusting for 
dilution. Growth curves were compiled over the course of several days and conclusions were 
made about the relative strain growth across several repeated growth curves. 
 
3.2.2. Culture filtrate and cell lysate analysis   
7H9 starter cultures were prepared as previously stated and grown to mid-late log phase 
of growth. Starter cultures were inoculated into Sautons + 0.05% Tween-20 to an OD600 of 0.1 
and grown at 37°C with 100 rpm shaking until cultures reached an OD600 of 0.6-0.8. Sautons + 
0.05% Tween-20 cultures were measured for their OD600 values. The volumes necessary to 
inoculate new cultures at a starting OD600 of 0.3 were centrifuged at 3500 x g for 15 mins. 
Supernatants were discarded and the pellets were resuspended gently in fresh Sautons alone. 
Sautons cultures were grown in non-treated plug-seal tissue culture flasks at 37°C with 100 rpm 
shaking for 3 days. Cultures were then centrifuged at 3500 x g for 15 mins. Supernatants were 
filtered through 0.45 um and 0.2 um filters and transferred from BSL-3 to BSL-2. These samples 
are hereby called culture filtrates. Culture filtrates were concentrated using 5 kDa molecular 
weight cut off (MWCO) Sartorius Vivaspin 20 Centrifugal Concentrators (Sigma).   
Cell pellets were resuspended in ice-cold PBS containing cOmplete, ethylenediamine-
tetraacetic acid (EDTA)-Free Protease Inhibitor. Cells were lysed using a Mini-Beadbeater-24 
with 0.25 g of Zirconia beads for each mL of cell pellet resuspension. Zirconia beads (0.1 mm) 
were sourced from BioSpec Products (Bartlesville, OK). Bead beating was performed at 1 min 
intervals of beating followed by 1 min rest on ice, repeated 7-8 times. Cell lysates were filtered 
through 0.45 um and 0.2 um filters and transferred from BSL-3 to BSL-2. Protein concentrations 
of all culture filtrates and cell lysates were determined using Pierce Bicinchoninic Acid (BCA) 
Protein Assay Kit (Thermo) according to manufacturer’s instructions. Samples were analyzed 
through Western blotting using α-EspD, α-EsxA, α-GroEL2, and α-Antigen 85 (Ag85) primary 
antibodies for all samples. 
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3.3. M. tb THP-1 infections  
3.3.1. Bacterial culture preparation 
7H9 starter cultures were grown to late log phase of growth as previously described. 24 h 
before M. tb infections of THP-1 cells were performed, starter cultures were resuspended and 
centrifuged at 300 x g for 2 min. The OD600 of the starter cultures was measured as described for 
growth curves. OD600 values were used to calculate the necessary volume of culture required to 
inoculate fresh 7H9 media at a starting OD600 of 0.1 to create the working culture. Working 
cultures were incubated at 37°C with 100 rpm shaking until the following day when infections 
were performed. 
 
3.3.2. THP-1 seeding and differentiation  
 THP-1 human monocyte cell line was purchased from American Type Culture Collection 
(ATCC) (Manassas, VA). THP-1 cells were revived from 3x106 cells/stocks in liquid nitrogen 
through rapid thawing and addition to Roswell Park Memorial Institute Medium (RPMI) 1640 
media + 10% previously heat-denatured fetal bovine serum (FBS). Cells were allowed to expand 
at 37°C + 5% CO2. Media was added to the THP-1 cultures as needed to maintain cell density 
between 3x105 cells/mL – 8x105 cells/mL. Once an appropriate volume of cells was achieved, 
THP-1s were centrifuged at 125 x g until pelleted and resuspended in RPMI + 10% FBS + 100 
ng/mL phorbol 12-myristate-13-acetate (PMA). Cells were immediately seeded at concentrations 
respective of the plate format used (Table 2). 24-well plates were seeded with 2x105 cells/well 
and 48-well plates were seeded with 1x105 cells/well. Cells were incubated at 37°C + 5% CO2 
for 3 days in media containing PMA, with differentiation monitored through microscopy daily. 
After 72 h, media containing PMA was replaced with RPMI + 10% FBS to allow cells to recover 
for 48 h at 37°C + 5% CO2 before infections were performed.  
 
Table 2: Seeding density values for THP-1 cell infections in 24-well and 48-well plates. 
Cell number Well volume Plate format 
1x105 cells/mL 2 mL 24-well plate 






3.3.3. Performing infections  
 The OD600 of the M. tb working cultures were measured as previously described for 
growth curves. The volume of M. tb culture needed for the appropriate multiplicity of infection 
(MOI) was calculated according to Formula 1. This volume was then prepared in the necessary 
volume of RPMI + 10% FBS to make infection solutions.  
 









=  volume of M. tb working culture needed in infection solution (mLs) 
Formula 1: Calculation to determine the volume of M. tb culture needed to be added to the 
infection solution.  
 
Infections performed for the production of cytokines were executed in a 24-well plate 
format with 2x105 THP-1 cells/well at an MOI of 10 for 24 h. Media on THP-1 cells was replaced 
with the prepared infection solutions and cells were allowed to incubate at 37°C + 5% CO2. After 
24 h, supernatants from each well were saved and cells were lysed in radioimmunoprecipitation 
(RIPA) buffer (0.05 M Tris pH 8.0, 0.15 M NaCl, 0.1% SDS, 1% NP-40, 1% Deoxycholic acid) 
for 10 min at 37°C. Lysate samples were then physically disrupted and individually passed 
through 0.2 um filters and transferred from BSL-3 to BSL-2 for analysis through Western blotting. 
Infections performed for cytotoxicity tests were performed in a 48-well plate format with 
1x105 THP-1 cells/well at an MOI of 5 for 3 days. Infection solutions were prepared by diluting 
the required volume of M. tb working cultures in RPMI media + 10% FBS. Media on the THP-1 
cells was replaced with the infection solutions and cells were allowed to incubate at 37°C + 5% 
CO2. After 3 days, cytotoxicity was measured through PrestoBlue or Lactate Dehydrogenase 
(LDH) Assay analysis.  
 
3.4. Cytotoxicity assays  
3.4.1. PrestoBlue  
Cell viability was measured through the addition of PrestoBlue Cell Viability Reagent 
(Thermo). This resazurin-based solution is converted into a fluorescent product by the reducing 
power of viable cells. The relative fluorescence output can be quantified and compared between 
infected and uninfected groups of cells. These measurements can then be converted into values 
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of percent cytotoxicity. PrestoBlue was diluted 1:10 in RPMI media + 10% FBS and allowed to 
incubate with cells for 15 min at 37°C. Fluorescence was read using a SpectraMax i3x with 
SoftMax Pro version 7.0.3 Data Acquisition and Analysis software (excitation at 560 nm and 
emission at 590 nm). The value for each well was calculated from the average of nine 
measurements from different areas within the well. The mean of all well values in each replicate 
group was then calculated and represents the average relative fluorescence units (RFUs) emitted 
for each treatment group. To calculate percent relative cytotoxicity, RFUs of the treatment group 
were compared to the RFUs of the uninfected group according to Formula 2. All statistical 




 x 100%   =  % Relative Cytotoxicity 
Formula 2: Percent relative cytotoxicity from mean relative fluorescence units.  
 
3.4.2. LDH  
LDH is a cytosolic enzyme released from cells when the plasma membrane is damaged. 
To perform the LDH Assay, the CyQUANT LDH Cytotoxicity Assay Kit (Thermo) was used. A 
set of uninfected cells were lysed according to the manufacturer’s instructions prior to 
transferring the infection supernatants to a clean 48-well plate. LDH assay was performed, and 
measurements were acquired with the SpectraMax i3x with SoftMax Pro version 7.0.3 Data 
Acquisition and Analysis software. A single independent experiment was performed and graphed 
using GraphPad without statistical analyses.  
 
3.5. ELISA  
Enzyme-linked immunosorbent assays (ELISA) were performed to detect IL1β and TNFα 
using the kits: Human IL-1 beta Uncoated ELISA and Human TNF alpha Uncoated ELISA 
(Thermo). ELISAs were performed according to manufacturer’s instructions. Samples were 
prepared neat and in several dilutions (1:2 through 1:40, as necessary) for evaluation. Samples 
were incubated in the IL1β ELISA plates for 3 h at RT or incubated in the TNFα ELISA plates 
for 2 h at RT. All incubation steps for the TNFα ELISAs were performed with 500 rpm shaking. 
Multi-well plates were read at 450 nm and 570 nm (background) using a the SpectraMax i3x with 
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SoftMax Pro version 7.0.3 Data Acquisition and Analysis software. Statistical analysis was 
performed with GraphPad Prism Version 8.4.3. 
 
3.6. Western blotting  
Samples were prepared with Nu-Polyacrylamide gel electrophoresis (PAGE) lithium 
dodecyl sulfate (LDS) buffer (Thermo) (1x final concentration with 2% beta-mercaptoethanol) 
and boiled for 10 min prior to being electrophoresed using NuPAGE 4-12%, Bis-Tris, 1.5 mm, 
protein gels (Thermo). Samples were electrophoresed at 200 V for 25 min. BLUelf Prestained 
Protein Ladder (3.5 kDa to 250 kDa) was purchased from FroggaBio Inc. (Concord, ON) and 
was used on each blot to track the mass of proteins in the sample. Protein was transferred to 
nitrocellulose membranes using the iBlot 2 Dry Blotting System (Thermo) according to 
manufacturer’s instructions. Membranes were blocked with 3% bovine serum albumin (BSA) in 
Tris-buffered saline + 0.05% Tween-20 (TBST) for 1 h at RT with gentle shaking. Primary 
antibodies were prepared in TBST + 1% BSA with the dilutions defined in Table 3 and incubated 
with membranes overnight at 4°C with gentle shaking. Appropriate fluorescent secondary 
antibodies were prepared at 1:10,000 dilutions in TBST + 1% BSA and incubated with 
membranes for 1 h at RT to allow for visualization on Li-Cor Odyssey CLx using Image Studio 
Version 5.2 software.  
 
Table 3: Primary antibodies were prepared in TBST + 1% BSA at the listed dilutions for Western 
blotting analysis. Fluorescent secondary antibodies against the appropriate animal source of the 
primary antibody were then used for imaging.  
Primary Antibody Dilution used Animal Source 
α-NLRP3 1:1000 Rabbit 
α-cleaved caspase-1 1:1000 Rabbit 
α-NF-κB 1:1000 Mouse 
α-pNF-κB 1:1000 Rabbit 
α-β-actin 1:1000 Mouse 
α-EspD 1:200 Rat 
α-EsxA 1:1000 Mouse 
α-Ag85 1:3000 Rabbit 
α-GroEL2 1:1000 Mouse 
 
 Antibodies against NLRP3, cleaved caspase-1, total nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB), and phosphophorylated NF-κB (pNF-κB) were purchased 
 
 25 
from Cell Signaling Technology (Danvers, MA). Antibody against β-actin was purchased from 
Abcam (Cambridge, UK).  
 
3.7. Recombinant EspD production  
3.7.1. Expression in E. coli  
The gene for EspD was encoded on pET28a vector with an N-terminal 6xHis-tag 
containing a kanamycin resistance cassette. This vector was named pJMC19 and was transformed 
into BL21(DE3) pLysS competent E. coli cells purchased from Agilent Technologies (Santa 
Clara, CA) through heat shock for 45 sec at 42°C and recovered in Luria Broth (LB) for 1 h at 
37°C before plating on LB agar and incubating overnight at 37°C. Recovered transformant 
colonies were inoculated into 10 mL of LB media and grown at 37°C overnight. Overnight 
cultures were added to 1 L of broth to a starting OD of 0.1 and grown at 37°C with 200 rpm 
shaking until reaching an OD of 0.5 at which point vector protein expression was induced using 
100 mM Isopropyl β-d-1-thiogalacto-pyranoside (IPTG) (final concentration). Induction was 
allowed to proceed for 18 h at 16°C with 200 rpm shaking.  
 
3.7.2. EspD protein purification under denaturing conditions  
Three liters of induced E. coli pJMC19 culture were combined and cells were pelleted at 
10,000 x g for 30 min. Cell pellets were resuspended in lysis/equilibrium/wash (LEW) buffer (50 
mM NaH2PO4, 300 mM NaCl, pH 8.0) and lysed using an Avestin french press achieving 15,000 
psi for two full passages. Lysate was clarified at 10,000 x g for 30 min and inclusion bodies were 
collected and solubilized in Denaturing Buffer (8M Urea, 50 mM NaH2PO4, 300 mM NaCl, pH 
8.0). Sample was added to Macherey-Nagel Protino Nickel-iminodiacetic acid (Ni-IDA) dry 
silica resin purchased from D-Mark Biosciences (Toronto, ON) in a gravity column. Resin with 
bound protein was washed with a series of Denaturing Buffers containing low concentrations (10 
mM, 20 mM, and 30 mM) of imidazole (IM). Protein was eluted with Denaturing Buffer + 300 
mM IM. LDS-PAGE electrophoresis was performed on samples taken over the course of the 
column purification. Elution samples determined to contain the most EspD protein were 
combined and promoted to refold through stepwise dialysis, slowing removing urea over 6-8 full 
buffer exchanges. Purified EspD samples prepared in this manner with all denaturing agents 
removed are hereby called refolded EspD. Protein samples were then concentrated with 30 kDa 
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MWCO Sartorius Vivaspin 20 Centrifugal Concentrators (Sigma) at 1000 x g. Final protein 
concentration was then determined with the Pierce BCA Protein Assay Kit (Thermo) according 
to manufacturer’s instructions. 
 
3.8. Recombinant EspD assays  
3.8.1. Native PAGE  
Native PAGE analysis of purified EspD protein is performed for varying concentrations 
(5 μg, 2.5 μg, and 1.25 μg per well) of protein. Samples were prepared in 1x final concentration 
NativePAGE Sample Buffer (Thermo). Electrophoresis was performed at 150 V for 90 min using 
the NativePAGE Novex Bis-Tris Gels (Thermo) with NativeMark Unstained Protein Standard 
(Thermo). Protein was transferred to nitrocellulose membranes as described above and Western 
blotting was performed with α-EspD primary antibody.   
 
3.8.2. TEM 
Purified EspD protein was diluted to a 1000 nM concentration in LEW buffer. 400 mesh 
Formvar/Carbon coated copper grids were glow discharged with Quorum Q150T ES. Protein 
samples were absorbed to the grid for 1 min, washed with water, and stained with 2% Uranyl 
Acetate for 1 min. The preparation was dried prior to imaging at 50k magnification using the 
Hitachi HT7700 microscope. TEM was performed at the Western College of Veterinary 
Medicine Imaging Centre.  
 
3.8.3. PIP strips and arrays  
PIP strips and PIP Arrays were purchased from Echelon Biosciences (Salt Lake City, UT). 
PIP Strip or PIP Array membranes were blocked in PBS + 0.01% Tween-20 (PBST) + 3% BSA 
for 1 h at RT with gentle shaking prior to incubation with purified EspD protein of interest at a 
concentration of 0.5 μg/mL in PBST + 3% BSA for 1 h at RT with shaking. Protein sample is 
removed, and membranes were washed with PBST alone followed by incubation with 1:200 α-
EspD primary antibody in PBST + 3% BSA overnight at 4°C with gentle shaking. Membranes 
were washed with PBST and incubated with 1:10,000 α-rat secondary antibody diluted in PBST 
+ 3% BSA for 1 hr at RT with shaking. Detection was performed using the Li-Cor Odyssey CLx 
using Image Studio Version 5.2 software.  
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3.8.4. Phospholipid-coated bead pull-downs  
50 μL slurries of each Lipid Coated Bead (Echelon) type, including PI3P, PI4P, PI5P, PA, 
PS, and control beads, were incubated with either 5 μg of purified EspD or 30 μg of culture 
filtrate/cell lysate sample. Beads were incubated with the protein sample overnight at 4°C while 
rotating. Mixtures were centrifuged at 800 x g and supernatants were removed. Beads were 
washed with 5 x sample volume of wash buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 0.25% 
Igepal) and centrifuged at 800 x g prior to removal of the supernatant. Wash steps were repeated 
4-5 times. Protein was eluted off the beads through the addition of LDS sample buffer and boiling. 
Western blotting using α-EspD antibody was performed as previously described.  
 
3.9. Phospholipid biosensors  
3.9.1. Maintaining COS-7 cells 
 COS-7 fibroblast-like monkey kidney cells (ATCC) were rapidly thawed from liquid 
nitrogen and resuspended in complete Dulbecco’s Modified Eagle Medium (DMEM) (DMEM + 
10% FBS, 1mM sodium pyruvate, 0.05 mg/mL gentamycin) and maintained in a treated tissue 
culture flask incubated at 37°C + 5% CO2. Cells were kept between 30-90% confluency and lifted 
with Trypsinization. Media was removed and cells were washed with PBS prior to the addition 
of trypsin for 3-5 min at 37°C to dissociate adherent cells from the flask. Complete DMEM was 
then added to neutralize the trypsin and cells were pelleted at 800 rpm for 8 min. Cells were 
resuspended in complete DMEM and counted on a hemocytometer using a trypan blue exclusion 
method with dilutions in 0.4% trypan blue dye. To expand, the appropriate volume of cells was 
aliquoted into a new flask with fresh complete DMEM and returned to 37°C + 5% CO2 incubation. 
For transfections, the volume of cells needed to seed 2.5x105 cells was resuspended in 2 mLs of 
complete DMEM in a 35 mm petri dish containing a non-treated coverslip. Cells were allowed 
to settle for 15 min and then were incubated overnight at 37°C + 5 % CO2.  
 
3.9.2. Maintaining RAW 264.7 cells 
RAW 264.7 murine macrophage cells (ATCC) were rapidly thawed from liquid nitrogen 
and resuspended in complete DMEM. Cells were incubated at 37°C + 5% CO2 in a treated tissue 
culture flask and maintained below 90% confluency. To count, cells were lifted with the addition 
of versene (0.5 mM EDTA.Na2.2H2O, 140 mM NaCl, 2.5 mM KCl, 9.5 mM Na2HPO4 1.5 mM 
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KH2PO4, 1 mM C6H12O6) and mixing before pelleting at 1200 x g for 5 min. Cells were 
resuspended in complete DMEM and counted using the trypan blue exclusion method on a 
hemocytometer with dilutions in 0.4% trypan blue dye. An appropriate volume of cells was 
returned to a treated tissue culture flask for expansion and incubated 37°C + 5% CO2. For 
transfections, the volume of cells needed to seed 2.5x105 cells was resuspended in 2 mLs of 
complete DMEM in a 35 mm petri dish containing a non-treated coverslip. Cells were allowed 
to settle for 15 min and then were incubated overnight at 37°C + 5 % CO2.  
 
3.9.3. Preparation of plasmids for transfection 
A library of fluorescent biosensors was established by sourcing previously constructed 
biosensor plasmids. Fluorescent biosensor plasmids pGFP-LactC2, pEGFP-2FYVE, and pGFP-
P4M were sourced from the Sergio Grinstein Lab at University of Toronto (Toronto, Canada), 
pGFP-PHDx3 was sourced from the Bernard Payrastre Lab at the French National Insitute of 
Health and Medical Research (Touloum, France) and pRFP-CDH, pGFP-CDH, pMRFP, and 
pMGFP were sourced from the Guangwei Du Lab at University of Texas (Houston, TX). 
Plasmids were transformed into E. coli Top10 competent cells by heat shock method described 
above. Successful transformants were then used to inoculate LB liquid media and grown 
overnight at 37°C with 200 rpm shaking. Liquid cultures were processed with the EndoFree 
Plasmid Maxi Kit according to the manufacturer’s instructions to purify large amounts of each 
plasmid. The EndoFree Plasmid Maxi Kit was purchased from Bio Basic (Markham, ON). 
 
3.9.4. Transfections 
To prepare for transfection, 2.0 μg of biosensor plasmid DNA of interest was diluted in 
Opti-MEM (Thermo) (2 μg/200 μL final concentration). This mixture was further added dropwise 
to a lipofectamine 2000 (Thermo) suspension in Opti-MEM (6 μg /200 μL) ensuring the 
DNA:lipofectamine ratio is 1:3-1:6. Solution was mixed gently and incubated at RT for 10 min. 
Media was aspirated and COS-7 or RAW 264.7 cells were washed with PBS followed by Opti-
MEM. Equal volumes of Opti-MEM and the DNA-lipofectamine mixture were added and the 
cells were allowed to incubate for 4 h at 37°C + 5% CO2. The transfection mixture was then 
removed and replaced with DMEM complete (without antibiotics) and cells were allowed to 
incubate for 16 h at 37°C + 5% CO2. Samples used for live imaging were then taken for confocal 
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imaging. Samples used to prepare fixed slides proceed through fixation protocol prior to 
imaging.  
 
3.9.5. Fixed Slide Preparation 
The fixation process was performed at RT, shielded from light. DMEM was removed and 
cells were washed with PBS. The coverslip was then allowed to soak for 2 min intervals in fresh 
PBS, repeating the soak 3 times with fresh PBS. The coverslip was then soaked in 4% 
Paraformaldehyde in PBS for 15 min prior to washing with PBS and quenching in 0.1 M glycine 
in PBS for 5 min. The coverslip was finally washed in PBS and excess liquid was drained before 
mounting to a glass slide with ProLong Gold Antifade mounting media (Thermo). The slide was 
then cured for 24 h in the dark.  
 
3.9.6. Confocal imaging 
 Slides or live cells were imaged using the Leica TCS SP8 confocal microscope using 
Leica Application Suite X software version 3.4.2.18368. Magnification was achieved using 63x 



















4.1. Mycobacterial EspD sequence alignment  
 Analysis of the protein sequence of EspD did not indicate the presence of any known 
functional domains and did not demonstrate sequence homology to any well characterized 
proteins. Therefore, sequences of EspD from several mycobacterial species were aligned to 
determine which residues are highly conserved (Figure 9). Residues exhibiting a high degree of 
conservation can indicate importance for protein structure and function as mutations to these 
residues are accepted less frequently than mutations in other residue positions (Capra and Singh, 
2007). CLUSTAL sequence alignment was performed using protein sequences of EspD from M. 
tb, BCG, M. bovis, M. leprae, and M. marinum (Figure 9).  
 
 
Figure 9: CLUSTAL omega multiple sequence alignment of EspD protein sequences from 
several Mycobacterial species using EMBL-EBI. Residues in red indicate a high level of 
conservation. Residues in blue indicate conservation to a lesser degree. Residues in black are not 
considered conserved. Red asterisks indicate residues targeted for mutation in this thesis.  
 
Unpublished work on EspD indicated that the protein may be capable of binding 
eukaryotic phospholipids in a specific manner (Figure 8). To target residues of EspD that may be 
involved in phospholipid binding, basic residues from highly conserved regions of the protein 
were selected for mutation. The positively charged side chains of these residues could interact 
with the negative head group of the phospholipid molecules to facilitate binding. Five residues 
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on EspD were targeted, indicated by the red asterisks on Figure 9. Specifically, the Arginines at 
positions 83, 92, 113, and 169 as well as the Lysine at position 115 were all mutated into Alanine 
residues. These mutations were performed on the espD gene of the pMDespACD vector. The 
resultant plasmids were transformed into the M. tb Erdman espA::Tn strain to investigate the 
impact of these mutations in M. tb.  
 
4.2. Characterization of M. tb espA::Tn strains expressing variant EspD proteins  
 EspD’s function within the mycobacterial cell has previously been identified (Chen et al., 
2012). This work established several strains of M. tb expressing EspD with single point mutations. 
Some of these strains were chosen for further characterization here, specifically M. tb espA::Tn 
pMDespACDW19R, M. tb espA::Tn pMDespACDW27R, and M. tb espA::Tn pMDespACDP31A. 
Additionally, the control strains M. tb espA::Tn pMD31, M. tb espA::Tn pMDespACDWT, and M. 
tb espA::Tn pMDespACDSTOP were included. These strains were analyzed alongside the newly 
constructed strains expressing EspD with mutations on conserved basic residues. Together, all M. 
tb strains were analyzed for differences in growth rates and secretion profiles.  
 
4.2.1. M. tb strains expressing variants of EspD demonstrate similar growth rates  
Using M. tb strains expressing variant EspD proteins, several independent growth curves 
were performed in both complete and minimal media types to screen for any differences in growth. 
Figure 10 demonstrates a single independent growth curve from each media type, complete 7H9 
media (Figure 10a) and Sautons minimal media (Figure 10b). Across all independent growth 
curves, there were no strains that consistently grew slower or faster than others. Additional 
growth curves (data not shown) demonstrated a similar spread of OD600 values due to unavoidable 
differences in culture preparations and OD600 measurements of the slow growing mycobacteria. 
Therefore, there appeared to be no differences in growth between these M. tb strains expressing 




Figure 10: Growth curve analysis of M. tb espA::Tn strains in (a) 7H9 complete media and (b) 
Sautons minimal media. 
 
4.2.2. M. tb strains expressing variants of EspD secrete EsxA at wild-type levels  
Secretion profile analyses were performed on M. tb espA::Tn strains expressing variant 
EspD proteins to monitor the impact of point mutations of EspD on ESX-1 associated secretion. 
EsxA and EspD were monitored specifically, as well as control proteins Ag85 and GroEL2. 
Secretion of EsxA indicates that the mutation present does not appear to affect the secretion of 
other ESX-1 members. As Ag85 is secreted from M. tb through a non-ESX-1 system it should be 
constitutively present in all samples, while GroEL2 is a cell-associated protein and should only 
be visualized if cells were lysed. The culture filtrate (CF) represents which proteins are 
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successfully being secreted, while the cell lysate (CL) represents which proteins are being 
expressed and remain stable within the M. tb cell.  
Results obtained in these experiments confirmed results of previously published data 
(Chen et al., 2012). When EspD was not expressed, as with M. tb espA::Tn pMDespACDSTOP 
and M. tb espA::Tn pMD31, EsxA was not secreted and stayed trapped within the cell (Figure 
11b). Analyses of M. tb espA::Tn pMDespACDW19R, M. tb espA::Tn pMDespACDW27R, and M. 
tb espA::Tn pMDespACDP31A were also performed. It was confirmed that these three strains were 
able to secrete EsxA (Figure 11a). Additionally, it was confirmed that M. tb espA::Tn 
pMDespACDP31A was secreting EspDP31A similarly to the M. tb espA::Tn pMDespACDWT strain, 
M. tb espA::Tn pMDespACDW27R has reduced ability to secrete EspDW27R, and M. tb espA::Tn 
pMDespACDW19R was unable to secrete EspDW19R (Figure 11a). This work confirms that the M. 
tb espA::Tn pMDespACDW19R strain can be utilized as a negative control for EspD secretion as 
it appears to lack EspD secretion alone without disrupting the secretion of other ESX-1 members. 
The newly constructed strains, M. tb espA::Tn pMDespACDR83A, M. tb espA::Tn 
pMDespACDR92A, M. tb espA::Tn pMDespACDR113A, M. tb espA::Tn pMDespACDK115A, and M. 
tb espA::Tn pMDespACDR169A were all capable of secreting both EsxA and EspD mutants 
(Figure 11a). M. tb espA::Tn pMDespACDR92A was consistently found to be most comparable to 






Figure 11: Western blotting analysis of (a) culture filtrates and (b) cell lysates from M. tb 
espA::Tn strains expressing variants of EspD using the indicated primary antibodies. Detection 





4.3. Cytotoxicity in THP-1 human macrophage cells  
 To monitor the impact of secreted EspD, several of these M. tb strains with varying 
secretion profiles were chosen for cytotoxicity experiments. Comparing these mutant strains for 
their ability to cause cell death during an infection determined whether these mutations led to a 
decrease in virulence. M. tb espA::Tn pMDespACDW19R was observed to cause a reduction in 
bacterial load compared to M. tb espA::Tn pMDespACDWT in the lungs and spleen of infected 
mice (Figure 6). This indicated that the M. tb espA::Tn pMDespACDW19R strain, lacking in EspD 
secretion alone, may be less virulent. To investigate this, a methodology was developed for 
working with human THP-1 cells. These monocytic cells were differentiated into macrophages 
and were infected with M. tb espA::Tn pMD31, M. tb espA::Tn pMDespACDWT, M. tb espA::Tn 
pMDespACDSTOP, M. tb espA::Tn pMDespACDW19R, or M. tb espA::Tn pMDespACDR92A and 
measured for their ability to cause cell death.  
 
4.3.1. Establishment of conditions for effective THP-1 preparation for infections 
To understand the impact of M. tb during early human infection, it is necessary to establish 
a relevant human macrophage cell line for in vitro experiments. THP-1 cells are human 
monocytes that can be terminally differentiated into macrophages with the use of a stimulant, 
PMA. Cells were treated with PMA and then allowed time to recover in media without PMA to 
establish differentiation into macrophages prior to infection. A methodology was developed here 
that established consistent results while working with THP-1 cells. To determine these 
parameters, several tests were performed establishing the appropriate cell density of THP-1s in 
the necessary plate format, the concentration of PMA required for differentiation, and the length 
of recovery time necessary prior to infection.  
Initial tests began with a previously used method, 1x106 THP-1 cells/well in a 24-well 
plate format or 5x105 THP-1 cells/well in a 48-well plate format with exposure to 5 ng/mL PMA 
for three days followed by five additional days of recovery in media free of PMA. The desired 
phenotype of adherent, terminally differentiated cells was not observed. Cells appeared to remain 
as monocytes and were crowded and stacked on top of one another (data not shown). Effectively 
differentiated cells should demonstrate a mound-like appearance, losing the refractive edges 
expected of non-adherent monocytes and having space to adhere to the plate and expand as they 
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become macrophage-like. Therefore, cell number was ultimately lowered to 2x105 THP-1 
cells/well in 24-well plates and 1x105 THP-1 cells/well in 48-well plates to avoid crowding.  
Further tests were performed to determine an appropriate concentration of PMA by 
treating THP-1 cells with incrementally higher concentrations of PMA for a three-day period. A 
macrophage-like phenotype began to appear in several cells around 20 ng/mL PMA (Figure 12a), 
however the majority of cells appeared differentiated at a concentration of 80 ng/mL PMA 
(Figure 12b). At 100 ng/mL PMA (Figure 12c), THP-1 cells demonstrated the desired phenotype 
and ultimately showed less stacking during the recovery days following removal of PMA. The 
length of exposure to PMA was consistently kept at three days, as work done by other members 
of the lab demonstrated shorter time periods at similar concentrations were less effective.  
 
 
Figure 12: Seeded THP-1 cells after three-day exposure to variable concentrations of PMA: (a) 
20 ng/mL, (b) 80 ng/mL, (c) 100 ng/mL. Cells were seeded at a density of 2x105 cells/well in a 
24-well plate format and imaged under 10x magnification. Arrows in (a) indicate THP-1 cells 





Lastly, an appropriate length of time for THP-1 recovery was determined. Throughout 
these tests, it was found that the overall age of the THP-1 cells contributed to how consistently 
the cells responded during infection experiments. Older THP-1 cells (>28 days since revival) 
were more likely to respond inconsistently to PMA treatment and therefore working with the 
cells within this timeline was kept a priority while determining the length of the recovery period. 
After treatment with 100 ng/mL PMA for three days, the majority of THP-1 cells displayed the 
desired phenotype. The previously used recovery time of five days led to cells stacking after 
remaining monocytes continued replicating (Figure 13a). Shortening the recovery time to two 
days, allowed the majority of THP-1 cells to remain in the desired phenotype (Figure 13b). This 
timeframe for recovery avoided expansion of any undifferentiated cells and also ensured that the 
THP-1s were infected prior to reaching 28-day post-revival age. 
 
 
Figure 13: THP-1 cells differentiated with 100 ng/mL of PMA and allowed to recover in media 
without PMA for (a) five days and (b) two days. Cells were seeded at a density of 2x105 cells/well 
in a 24-well plate format and imaged under 10x magnification. 
 
4.3.2. PrestoBlue analysis reveals a consistent trend of reduced cytotoxicity with M. tb 
espA::Tn pMDespACDW19R compared to M. tb espA::Tn pMDespACDWT 
 THP-1 cells were infected with selected M. tb strains to examine their cytotoxic effect. 
Preliminary infection experiments were performed at varying MOIs (0.2, 1, 5, and 10) and in 
varying multi-well plate formats before confirming the final conditions used for these 
experiments. To characterize strains for their cytotoxic ability, infections were performed in 48-
well plate formats at 1x105 THP-1 cells/well at an MOI of 5 for 72 h. Using M. tb espA::Tn 
pMD31, M. tb espA::Tn pMDespACDWT, M. tb espA::Tn pMDespACDSTOP, M. tb espA::Tn 
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pMDespACDW19R, and M. tb espA::Tn pMDespACDR92A cytotoxicity experiments were 
performed primarily by measuring cell viability using PrestoBlue reagent. This resazurin-based 
solution is converted into a fluorescent product by the reducing power of viable cells. The relative 
fluorescence output was quantified and compared between infected and uninfected groups of cells. 
These measurements were then converted into values of percent cytotoxicity. 
The least cytotoxic strain was the strain missing the entire espACD operon, M. tb espA::Tn 
pMD31 (Figure 14). The highest level of cytotoxicity was exhibited by M. tb espA::Tn pMD-
espACDWT (Figure 14). M. tb espA::Tn pMDespACDSTOP, M. tb espA::Tn pMDespACDW19R, and 
M. tb espA::Tn pMDespACDR92A appeared less cytotoxic than M. tb espA::Tn pMDespACDWT 
(Figure 14). The lower cytotoxicity observed with the M. tb espA::Tn pMDespACDW19R, which 
unlike M. tb espA::Tn pMDespACDSTOP can secrete EspA, EspC, EsxA, and EsxB and is only 
missing EspD secretion, was observed repeatedly (Figure 14). Statistical analyses demonstrated 
no significant differences between M. tb espA::Tn pMDespACDW19R and M. tb espA::Tn pMD-
espACDWT, however this phenotype remained consistent across three independent experiments. 
 
 
Figure 14: Percent relative cytotoxicity of M. tb espA::Tn strains expressing the indicated plasmid 
in PMA-differentiated THP-1 human macrophage cells analyzed through PrestoBlue. Infections 
were performed at an MOI of 5 for 72 h. Repeated measures one-way ANOVA (p = 0.2978) 
performed with GraphPad Prism Version 8.4.3. Values represent the mean of three independent 
experiments. Error bars represent standard error of means. 
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4.3.3. LDH analysis demonstrates a similar trend of reduced cytotoxicity with M. tb 
espA::Tn pMDespACDW19R compared to M. tb espA::Tn pMDespACDWT 
A parallel approach to examine cytotoxicity was performed through measurement of LDH, 
a cytosolic enzyme released from cells when the plasma membrane is damaged. A single LDH 
experiment was performed on M. tb infected THP-1 macrophages to corroborate the results 
obtained through PrestoBlue analysis. Here, the trend demonstrated that M. tb espA::Tn 
pMDespACDW19R was less cytotoxic than M. tb espA::Tn pMDespACDSTOP and M. tb espA::Tn 
pMDespACDWT (Figure 15). However, despite confirming this trend, the LDH measurement 
technique appeared to give unrealistic values for relative percent cytotoxicity. Not all values fell 
within the 0-100% range and several were roughly double the values obtained through the 
PrestoBlue assay (Table 4). Additionally, the cytotoxicity measured with M. tb espA::Tn 
pMDespACDR92A was unexpectedly low for a strain with a wildtype-like secretion profile and 
contradicted what was observed across several PrestoBlue experiments. As the values obtained 
through the LDH assay appeared less realistic, this methodology was forgoed in favour of 
PrestoBlue analysis. The phenotype exhibited by M. tb espA::Tn pMDespACDW19R in the LDH, 
PrestoBlue, and the unpublished mouse infection analyses collectively suggest that this strain is 









Figure 15: Percent relative cytotoxicity of M. tb espA::Tn strains expressing the indicated plasmid 
in PMA-differentiated THP-1 human macrophage cells analyzed through LHD assay. Infections 
were performed at an MOI of 5 for 3 days. Data points represent results after a single experiment, 
averaging only three replicates of each group.  
 
Table 4: Summary of the percent cytotoxicity values obtained for THP-1 cells infected with 
selected M. tb espA::Tn strains and analyzed through PrestoBlue and LDH assays.  
M. tb espA::Tn strain Average % Cytotoxicity (PrestoBlue) % Cytotoxicity (LDH) 
pMD31 28.7 67.3 
pMDespACDWT 59.7 109.8 
pMDespACDSTOP 54.3 107.8 
pMDespACDW19R 50.1 93.3 
pMDespACDR92A 51.9 53.9 
 
4.4. IL1β and TNFα production is suppressed in M. tb espA::Tn pMDespACDW19R  
ESX-1 dependent cell death in M. tb infected macrophages has been shown to correspond 
with the induction of pro-inflammatory cytokines (Chen et al., 2013a). As M. tb espA::Tn 
pMDespACDW19R appeared to cause a decrease in macrophage cell death compared to M. tb 
espA::Tn pMDespACDWT, production of IL1β and TNFα was monitored to determine if this 
phenotype corresponds to pro-inflammatory cytokine production. THP-1 cells were infected with 
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M. tb espA::Tn pMD31, M. tb espA::Tn pMDespACDWT, M. tb espA::Tn pMDespACDSTOP, M. 
tb espA::Tn pMDespACDW19R, or M. tb espA::Tn pMDespACDR92A and infection supernatants 
were measured 24 h post-infection through ELISA.  
Pro-inflammatory cytokine production was reduced in the case of THP-1 infections with 
M. tb espA::Tn pMDespACDW19R compared to M. tb espA::Tn pMDespACDWT (Figure 16). This 
difference is statistically significant in the case of IL1β (Figure 16a). Results for IL1β and TNFα 
displayed a consistent trend across all strains. Both IL1β and TNFα production in THP-1 cells 
induced by M. tb espA::Tn pMD31 and M. tb espA::Tn pMDespACDR92A were found to be similar 
to one another and were not significantly different from M. tb espA::Tn pMDespACDWT (Figure 
16). The M. tb espA::Tn pMDespACDSTOP strain induced a higher production of pro-
inflammatory cytokines in THP-1 cells than M. tb espA::Tn pMDespACDWT (Figure 16). These 
results demonstrate that ESX-1 dependent cell death does not necessarily correspond with an 
increase in pro-inflammatory cytokine production. 
 
 
Figure 16: M. tb espA::Tn strains expressing the indicated plasmids infected PMA-differentiated 
THP-1 human macrophages for 24 h at an MOI of 10 before supernatants were collected for 
ELISA analysis for (a) IL1β concentration and (b) TNFα concentration. Repeated measures one-
way ANOVA (IL1β: p = 0.0362, TNFα: p = 0.2960) performed with GraphPad Prism Version 
8.4.3. Statistically significant differences with p < 0.05 indicated with (*). Values represent the 
mean of three independent experiments. Error bars represent standard error of means.  
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4.5. Monitoring expression levels of proteins of pro-inflammatory pathways  
 To further investigate the differences observed in the production of pro-inflammatory 
cytokines, M. tb infected THP-1 cell lysates were analyzed through Western blot. Several proteins 
involved in the pathways leading to pro-inflammatory cytokine production were detected in the 
infection lysates collected 24 h post-infection. To investigate the differences seen in IL1β 
production, NLRP3 and cleaved caspase-1 were monitored to observe activation of the NLRP3 
inflammasome (Broz and Dixit, 2016). Additionally, the presence of total NF-κB and 
phosphorylated NF-κB were observed as the NF-κB signaling pathway is highly interconnected 
with TNFα signaling (Hayden and Ghosh, 2014). 
 
4.5.1. NLRP3 and cleaved caspase-1  
Western blots detecting NLRP3 and cleaved caspase-1 were loaded with 15 μg 
protein/well of the lysates of THP-1 cells infected with the selected M. tb strains. The detected 
levels of NLRP3 were similar across all infected lysates, including the uninfected group (Figure 
17). Attempts were made to optimize the signal by increasing the amount of sample. However, 
blots with more than 15 μg of total protein/well did not display improved NLRP3 signal. Cleaved 
caspase-1 was not detected at any protein concentration. Additional tests may be needed to 
confirm the functionality of the α-cleaved caspase-1 primary antibody. Western blots were 
performed using each of these primary antibodies (NLRP3, cleaved caspase-1, total NF-κB, pNF-
κB, and β-actin) on multiple sets of infected THP-1 cell lysates. Blots are representative of the 
results observed across all samples, however any minor signal differences observed in these blots 







Figure 17: M. tb espA::Tn strains expressing the indicated plasmids infected PMA-differentiated 
THP-1 human macrophages for 24 h at an MOI of 10. Cell lysates were collected for Western 
blotting to identify the presence of NLRP3 and cleaved caspase-1. Primary antibodies were used 
at a 1:1000 dilution incubated overnight before detection with fluorescent secondary antibody.  
 
4.5.2. NF-κB phosphorylation 
Western blots detecting total NF-κB, pNF-κB, and β-actin were performed with 10 μg of 
total protein/well from the infected THP-1 lysate samples. Similar to the signal observed with 
NLRP3, there were no detectable differences in NF-κB phosphorylation in THP-1 cells infected 
with the different M. tb strains (Figure 18). If there were any differences in phosphorylation of 
NF-κB caused by any of the selected M. tb strains, they were missed at the single timepoint of 24 
h post-infection. The signal visualized here appears to be the basal level of NF-κB and pNF-κB, 
indicated by the similarity of signals in all infected lysates to the signal of the uninfected lysate.  
 
Figure 18: M. tb espA::Tn strains expressing the indicated plasmids infected PMA-differentiated 
THP-1 human macrophages for 24 h at an MOI of 10. Cell lysates were collected for Western 
blotting to identify the presence of total NF-κB and pNF-κB. β-actin was used as a loading control. 
Primary antibodies were used at a 1:1000 dilution incubated overnight before detection with 
fluorescent secondary antibody.   
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4.6. Production of recombinant EspD protein  
Through the investigation of M. tb espA::Tn pMDespACDW19R, which is unable to secrete 
EspD, it is clear this protein has a function contributing to the M. tb infection in macrophages. 
To understand the role of secreted EspD, efforts to express and purify the protein from E. coli 
were made to facilitate investigation of its biochemical properties. Purification of this protein was 
attempted under both non-denaturing (native) conditions as well as denaturing conditions.  
 
4.6.1. Non-denaturing purification of EspD 
Many attempts were made to purify recombinantly expressed EspD from E. coli in its 
native form. A native purification approach that provides high purity and yield has not yet been 
developed for EspD and is necessary in order to perform further biophysical analyses including 
circular dichroism (CD) and dynamic light scattering (DLS). Through these purification trials, a 
proposed protocol was developed, however it was only partially successful (Figure 19). This 
proposed protocol includes three levels of purification: His-tag purification, anion-exchange 
chromatography (AEC), and SEC. Here, this protocol will be discussed and recommendations 






Figure 19: Tentative non-denaturing purification protocol for recombinantly produced EspD 
from E. coli. Buffer A: 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 7.4. Buffer B :20 
mM Tris-HCl, 150 mM NaCl, 2.5 mM CaCl2; pH 8.4. Buffer C: 20 mM Tri-HCl, pH 8.0, eluting 
with 1M NaCl, pH 8.0. All column buffers should be degassed and filtered prior to use. Total 
protein concentration of the sample to be monitored through BCA Assay and purity observed 
through LDS-PAGE. Samples can be concentrated when necessary with appropriate MWCO 
Sartorius Vivaspin 20 Centrifugal Concentrators. 
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Expression in E. coli:  
The protein of interest was encoded in the pET28a-based vector, pJMC19, and 
transformed into E. coli BL21(DE3) pLysS. The His-tag was encoded on the N-terminus of EspD 
with a Thrombin cleavage site located between the encoded tag and the protein itself. Expression 
was controlled under the lac operon and therefore induced by the addition of IPTG once the E. 
coli pJMC19 cultures reached mid-log phase of growth in LB media. Induction was allowed to 
proceed overnight before collecting the cell pellets. 
Induction conditions were established after observing protein expression at varying 
temperatures. Culture samples were taken prior to the addition of IPTG (pre-induction) and after 
induction was allowed to proceed in full (post-induction). After the addition of IPTG, several 
cultures were allowed to incubate at 37°C for 4 h, while others were incubated overnight at 16°C. 
Samples were then diluted relative to the OD600 of the culture at the time the sample was taken. 
Evaluation of pre-induction and post-induction samples from all cultures was performed through 
LDS-PAGE and Coomassie blue staining. The target protein was visualized at ~25 kDa in size 
and induction was observed in samples across both temperatures (Figure 20). Consistently, more 
of the target protein was present relative to the contaminating proteins in the post-induction 
samples of cultures induced overnight at 16°C than was observed with cultures induced at 37°C 
for 4 h. These conditions were selected moving forward.  
 
 
Figure 20: EspD protein expression tests of E. coli pJMC19 cultures. Samples taken before (pre) 
and after (post) induction with IPTG at 16°C overnight or 37°C for 4 h. Samples were analyzed 
through LDS-PAGE and Coomassie blue staining.   
 
 47 
Buffer tests and lysis: 
Preliminary buffer tests established that buffers of lower ionic strength (< 200 mM NaCl) 
lead to greater EspD aggregation than buffers of higher ionic strength (300-500 mM NaCl). 
Eventually, a buffer containing 50 mM sodium phosphate, 300 mM sodium chloride, 10 mM 
imidazole; pH 7.4 was established as the base formula for EspD’s purification buffer (Buffer A). 
This buffer was used for lysis, equilibrium, and wash steps throughout the His-tag purification 
and SEC steps. Buffer A is used to resuspend the centrifuged bacterial cell pellets collected after 
induction. Lysis was then performed using an Avestin French press. Pressure was allowed to 
reach > 15000 psi for two full passages to ensure effective lysis. Additional passages can be 
damaging to the protein and should be avoided when possible.  
 
His-tag purification: 
The clarified lysate was applied to HisPur Cobalt resin, capturing the protein through its 
His-tag. Resin was washed with Buffer A, followed by washes with gradual increases in 
imidazole concentrations (10-30 mM imidazole). Elutions were performed using Buffer A 
containing 300 mM imidazole (elution buffer). Samples were taken from the flow through (FT) 
of each stage of the column purification. Monitoring through LDS-PAGE allowed observation of 
the relative concentration of EspD present in each stage (Figure 21). Total lysate samples 
demonstrated the impurity of the starting sample and the high concentration of protein at the 
target size. Initial passage through the HisPur column and washes removed much of the 
contaminating protein, but also lead to loss of target protein. A much larger volume of HisPur 
resin was required in the purification demonstrated by Figure 21 to capture an appropriate amount 
of target protein from the lysate. After the addition of elution buffer, typically the first and second 
column volumes (CV) of buffer contained the highest concentration of target protein. Volumes 
of elution buffer beyond three CVs were found to be redundant and did not release any further 
bound protein. There remained a significant amount of target protein loss that occurred during 
His-tag purification. EspD remained bound to the resin after elution attempts were performed. 
Attempts to increase the imidazole concentration in the elution buffer were unsuccessful at 
releasing more protein from the resin. Optimization of these steps is still needed to provide higher 




Figure 21: LDS-PAGE electrophoresis of samples from the stages of small scale His-tag 
purification of recombinant EspD through HisPur cobalt resin. Protein was visualized with 
Coomassie blue staining. FT = flow through, IM = mM concentration of imidazole present in 
wash buffer (50 mM NaH2PO4, 300 mM NaCl, pH 7.4), E1 = elution fraction 1, E2 = elution 
fraction 2, E3 = elution fraction 3. 
 
Buffer exchange and His-tag cleavage: 
High concentrations of imidazole should be immediately dialyzed out of elution fractions 
containing EspD. Buffer exchange was performed into Thrombin activity-friendly Buffer B (20 
mM Tris-HCl, 150 mM NaCl, 2.5 mM CaCl2; pH 8.4). Biotinylated Thrombin enzyme was added 
to the protein sample to remove the His-tag. LDS-PAGE evaluation confirmed the cleavage 
success (Figure 22). A streptavidin column was used to remove the enzyme from the protein 
sample before dialyzing the sample back into Buffer A. Further application to fresh HisPur Cobalt 
resin binds EspD protein that remains linked to its His-tag. The flow through from this column 




Figure 22: Thrombin cleavage analysis of recombinant EspD protein from 0 min to 90 mins. 
Samples were electrophoresed through LDS-PAGE and gel was stained with Coomassie blue.  
 
Anion exchange and size exclusion chromatography: 
The remaining purification steps were not completed in their proposed order from Figure 
19. It has been advised that AEC be performed with the sample following His-tag removal. This 
process can release contaminating proteins that may remain bound to EspD itself prior to 
application to SEC as the final step of purification. Due to EspD’s low predicted isoelectric point 
of 4.1, anion exchange will be performed using the available Q Sepharose column. Trials of this 
purification stage should begin with Buffer C (20 mM Tri-HCl, pH 8.0, eluting with 1M NaCl, 
pH 8.0) and may require further optimization.  
Attempts using SEC were previously performed immediately after His-tag removal. 
Higher concentrations of protein were necessary, therefore the procedure should be scaled 
upwards, as indicated in the proposed protocol. Buffer A was used through SEC tests and no 
EspD aggregation was observed at this stage. Moving forward, SEC should be performed using 
a Sephacryl S-400 column to effectively purify EspD in its large oligomeric state. Each of these 
chromatography steps will require confirmation that an effective elution peak is observed 
indicating high concentration of fractionated EspD from the column. Once a high yield and pure 






Other insights into the purification of recombinant EspD under non-denaturing conditions: 
Several practices were found to promote the aggregation of EspD in solution and should 
be avoided while further establishing purification methodology. Prior to selecting the current 
three stages of purification as His-tag purification, AEC, and SEC, salting out methods were 
attempted as well. Ammonium sulfate treatment led to the formation of insoluble precipitates 
made up predominantly of EspD protein. Additionally, it was not found to be an effective 
purification technique as EspD did not appear to precipitate at any specific salt concentrations. It 
is recommended that this method of purification not be attempted in the future for EspD.  
Initial thermostability tests with His-tag purified EspD samples revealed that aggregation 
occurred over a brief period of time at any temperature. As well, the protein was sensitive to 
freeze-thawing. Due to these issues, purification is recommended to proceed uninterrupted until 
the protein sample has proceeded through His-tag cleavage, enzyme removal, and buffer 
exchange into Buffer A. Failure to remove the His-tag enzymatically led to aggregation of the 
EspD samples during storage. Protein samples appeared to remain stably stored for a longer 
period of time (> several weeks at 4°C) after His-tag removal than protein samples that remain 
His-tag linked (no longer than a few days).  
Initial purification trials were performed using a Nickel-IDA silica-based resin for His-
tag purification. This dried silica resin was a major cause of EspD aggregation. After many 
attempts to find a buffer that allowed for use of this resin with EspD, it was finally concluded 
that the resin itself instigated the protein insolubility. Additionally, His-tag resins using Nickel, 
opposed to Cobalt, led to higher amounts of protein loss during His-tag purification due to the 
higher strength of Nickel-His binding. As effective elutions of EspD from the His-tag purification 
column were a consistent issue, Nickel based resins are expected to only amplify this issue further.  
 
4.6.2. Denaturing purification of recombinant EspD  
Denaturing conditions were used to purify recombinant EspD protein from inclusion 
bodies of E. coli cultures. Protein expression was induced, and bacterial cells were collected and 
lysed, as mentioned in the non-denaturing protocol. Inclusion bodies were collected, washed, and 
solubilized in Denaturing Buffer (50 mM sodium phosphate, 300 mM sodium chloride, 8M urea, 
pH 8.0) before mixing with Nickle-IDA silica resin for His-tag purification. This mixture was 
washed with Denaturing Buffer containing low concentrations of imidazole (10-30 mM 
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imidazole) to remove nonspecifically bound proteins and eluted with Denaturing Buffer 
containing 300 mM imidazole. Purity was determined by observation through LDS-PAGE and 
Coomassie blue staining (Figure 23). The elution fraction containing the target protein was then 
dialyzed in a stepwise fashion to remove all urea and imidazole leaving the protein in the Assay 
Buffer (50 mM sodium phosphate, 300 mM sodium chloride, pH 8.0). Dialysis was the most 
practical methodology available to promote refolding of the purified EspD sample, however, it is 
worth noting that these samples may contain a considerable portion of unfolded or misfolded 
protein. Protein concentration was determined by BCA assay. Under denaturing conditions, 
purification of recombinant EspD yielded 1-5 mg of total protein with reasonable purity (Figure 
23). This was a large improvement relative to the purification trials performed previously. Due 
to aggregation issues, the EspD purifications performed under non-denaturing conditions led to 
final protein yields of < 250 μg in total and contained more contamination (Figure 21). 
 
 
Figure 23: LDS-PAGE analysis of His-tag purification of EspD performed under denaturing 
conditions. FT = flow through, IM = concentration of imidazole (mM) present in wash buffer (50 
mM NaH2PO4, 300 mM NaCl, 8M urea, pH 8.0), E1 = elution fraction 1, E2 = elution fraction 2. 
  
4.7. Analysis of purified recombinant EspD protein 
 Unpublished work performed on recombinant EspD protein produced through small-scale 
non-denaturing purification displayed that EspD may form large oligomers and may bind 
eukaryotic phospholipids (Figures 7 & 8). To investigate if these features might also be seen with 
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recombinant EspD purified from E. coli under denaturing conditions, protein samples were 
dialyzed to remove denaturing agents in the buffer and then analyzed through Native-PAGE, 
TEM, and phospholipid binding assays.  
 
4.7.1. Structural analysis with Native-PAGE and TEM 
EspD was analyzed through Native-PAGE and TEM to observe oligomerization of the 
purified protein. Native-PAGE was performed on decreasing concentrations of EspD and 
visualized through Western blot using α-EspD primary antibody (Figure 24). Native-PAGE 
demonstrated that EspD appears to exist predominantly in oligomeric forms in sizes upwards of 
400 kDa in size, similar to what was seen with the unpublished SEC data (Figure 7a). The 
observed smear may imply there is not one static size of the EspD oligomer and instead the 
protein may bind with itself in a non-specific manner, allowing for oligomers of various sizes. 
There did not appear to be any banding pattern that could represent a monomer or dimer, etc. 
However, the oligomeric smear in the well loaded with 5 μg of EspD appeared to extend to lower 
sizes (60-80 kDa), which may imply that EspD can exist in these smaller oligomers to a lesser 
degree. This could also be evidence of contaminating proteins binding non-specifically to the α-
EspD antibody during Western blotting.  
 
 
Figure 24: Native-PAGE of purified and refolded EspD protein detected through Western blotting 
with α-EspD primary antibody and fluorescent secondary antibody. 
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EspD samples were diluted to a 1000 nM concentration in the Assay Buffer and were 
absorbed onto 400 mesh TEM grids, stained with a tungsten negative stain, and imaged at 50k 
magnification using the Hitachi HT7700 microscope (Figure 25). EspD protein prepared here 
was unable to be imaged through this methodology without causing the protein to aggregate. 
Previous unpublished data visualized recombinant EspD protein in an unaggregated state 
displaying chain-like oligomeric structure (Figure 7b).  
 
 
Figure 25: TEM images taken at 50k magnification of purified and refolded EspD protein. Images 
were obtained at the Western College of Veterinary Medicine Image Centre on the Hitachi 
HT7700 TEM. Yellow circles indicate some large areas of aggregated protein.  
 
4.7.2. Phospholipid-EspD binding assays 
 Unpublished work on recombinant EspD uncovered that the protein appears to bind 
specifically to several eukaryotic phospholipids (Figure 8). The protein’s ability to bind 
eukaryotic phospholipids may contribute to the impact secreted EspD appears to have during M. 
tb infections of macrophages. Here, recombinant protein samples purified from E. coli under 
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denaturing conditions were refolded and binding tests were performed using commercially 
available phospholipid membranes and beads. 
Membranes embedded with eukaryotic phospholipids were incubated with 100 nM 
purified EspD protein. PIP Strips include fifteen different phospholipids at 100 pmol/spot, while 
PIP Arrays include eight different phosphoinositides at concentrations from 100 pmol/spot 
decreasing to 1.56 pmol/spot. Membranes were further probed with α-EspD antibody to assess 
which of the phospholipids bind EspD. The PIP Strips identified that EspD was predominantly 
bound to PA and the phosphatidylinositol monophosphates, including PI3P, PI4P, PI5P (Figure 
26a). The PIP Arrays further investigated EspD’s ability to bind phosphoinositides. EspD again 
demonstrated binding to phosphatidylinositol monophosphates (Figure 26b). Taken together, 
EspD appeared to consistently bind strongly to PI4P.  
 
 
Figure 26: Commercially available membrane (a) PIP Strip (b) PIP Array incubated with 100 nM 
purified and refolded EspD protein and detected through Western blotting with α-EspD primary 
antibody and fluorescent secondary antibody. LPA = lysophosphatidic acid, LPC = 
lysophosphocholine, PI = phosphatidylinositol, PIP = phosphorylated phosphatidylinositol 
species, PEA = phosphatidyl-ethanolamine, PC = phosphatidylcholine, S1P = sphingosine 1-





Additional phospholipid binding tests were performed using commercially available 
agarose beads coated in phospholipids of interest. Beads were incubated with 500 nM purified 
protein and washed to remove non-specifically bound protein. Beads were boiled to release the 
remaining bound protein and samples were evaluated through LDS-PAGE and α-EspD probing. 
Signal observed from pull-downs with control beads indicate non-specifically bound protein as 
these beads are comprised of blocked agarose and are not coated in phospholipids. EspD 
demonstrated binding towards PA and PI4P (Figure 27). This phenotype further corroborates the 
results observed using PIP Strips and PIP Arrays from Figures 8 & 26.   
 
 
Figure 27: Commercially available beads coated in the indicated phospholipids were incubated 
with 500 nM purified and refolded EspD protein. Bound protein was detected through Western 
blotting with α-EspD primary antibody and fluorescent secondary antibody. PIP = 
phosphorylated phosphatidylinositol species, PA = phosphatidic acid, PS = phosphatidylserine. 
 
4.8. Phospholipid bead pull-down with M. tb produced EspD 
To further investigate EspD’s ability to bind PI4P, samples of M. tb cultures were utilized 
in pull-down experiments using phospholipid coated beads. Original attempts were made using 
cell lysate samples of M. tb espA::Tn pMDespACDWT and M. tb espA::Tn pMDespACDSTOP to 
determine whether a pull-down experiment could be successful using a mixture of proteins as 
opposed to a purified protein sample. EspD was able to be pulled down from the M. tb espA::Tn 
pMDespACDWT cell lysates, with a stronger signal for EspD in the case of the PI4P beads than 
with the control beads (Figure 28). Bead washing was not rigorous enough to effectively remove 
the non-specifically bound protein, therefore true binding to PI4P beads may be weaker than 
observed. Nonetheless, this assay stands as a proof of concept that specific proteins may be able 




Figure 28: Cell lysate samples (expressed proteins) of the M. tb espA::Tn strains indicated were 
used to perform phospholipid-coated bead pulldowns with PI4P and control beads.  
 
To attempt to confirm that secreted EspD is capable of this binding, culture filtrate 
samples for M. tb espA::Tn pMDespACDWT and M. tb espA::Tn pMDespACDSTOP were made. 
Due to the low relative concentration of EspD in culture filtrates, large volumes (6 x that of 
standards culture filtrate Western blots) were prepared. Each culture filtrate sample was 
confirmed for the presence of Ag85 and absence of GroEL2 to ensure the bacteria was not lysed 
during sample preparation. These filtrates were concentrated, and pull-downs were performed 
using PI4P and control beads. This assay displayed a high amount of background signal, however, 
Figure 29 demonstrated that secreted EspD was pulled down from M. tb espA::Tn 
pMDespACDWT culture filtrate sample using PI4P beads. Despite the faint signal, this result 
corroborates the PI4P binding phenotype observed in recombinant EspD purified under both non-
denaturing (Figure 8) and denaturing conditions (Figures 26 & 27).  
 
 
Figure 29: Culture filtrate samples (secreted proteins) of the M. tb espA::Tn strains indicated were 




4.9. Generation of mammalian cells expressing phospholipid biosensors  
Establishing the binding of secreted EspD to eukaryotic phospholipids, especially PI4P, 
leads to interest in exploring this phenotype within the host cell during infection. To begin 
monitoring the potential impact to the eukaryotic host, a collection of fluorescent biosensor 
plasmids was established for the purposes of monitoring phospholipids of interest within 
eukaryotic cells (Table 5). These plasmids encode probes which bind specifically to the target 
phospholipid. Probes are expressed attached to either green fluorescent protein (GFP) or red 
fluorescent protein (RFP) to allow visualization through confocal microscopy.  
 
Table 5: Fluorescent biosensor plasmid library for the sensing of eukaryotic phospholipids.   
Biosensor Name Phospholipid Target Source 
pGFP-LactC2 PS Sergio Grinstein at the University of Toronto 
pEGFP-2FYVE PI3P Sergio Grinstein at the University of Toronto 
pGFP-P4M PI4P Sergio Grinstein at the University of Toronto 
pGFP-PHDx3 PI5P Bernard Payrastre at the French National Institute 
of Health and Medical Research 
pRFP-CDH PA Guangwei Du at the University of Texas 
pGFP-CDH PA Guangwei Du at the University of Texas 
pMRFP PA Guangwei Du at the University of Texas 
pMGFP PA Guangwei Du at the University of Texas 
 
Plasmids were first evaluated for their functionality and ability to produce fluorescent 
signal. Transfections were performed with a lipofectamine method using an easily transfectable 
cell line, COS-7 fibroblast-like monkey kidney cells. Using confocal microscopy, it was 
determined that all plasmid biosensors were functional (Figures 30 & 31). All biosensors 
demonstrated strong fluorescent signal and displayed localization patterns that appeared distinct 





Figure 30: COS-7 monkey kidney fibroblast cells transfected with (a) pGFP-LactC2, sensing PS 
(b) pEGFP-2FYVE, sensing PI3P (c) pGFP-P4M, sensing PI4P (d) pGFP-PHDx3, sensing PI5P. 
Live cell imaging was performed 16 h post-transfection on the Leica TCS SP8 confocal 
microscope using Leica Application Suite X software version 3.4.2.18368. Magnification was 





Figure 31: COS-7 monkey kidney fibroblast cells transfected with (a) pCDH-RFP (b) GFP-PASS 
(c) pM-RFP (d) GFP-PASS. These plasmids were all constructed to sense PA. Live cell imaging 
was performed 16 h post-transfection on the Leica TCS SP8 confocal microscope using Leica 
Application Suite X software version 3.4.2.18368. Magnification was achieved using 63x oil 









After confirming functionality of the biosensor plasmids, the next necessary step was to 
develop a way to utilize these plasmids in a relevant macrophage cell line. Ideally, human 
macrophage cells could be used to most accurately represent human M. tb infections. However, 
transfections were unable to be performed in THP-1 cells using a lipofectamine-based method. 
Additionally, attempts were made using a THP-1 specific nucleofection kit, but ultimately this 
cell line was not able to be transfected effectively with the biosensor plasmids. The next available 
relevant cell line was RAW 264.7 cells, a murine macrophage cell line. Unlike THP-1 cells, RAW 
264.7 cells are not terminally differentiated and replicate with a doubling time of ~11 hours 
(Sakagami et al., 2009). Without terminal macrophages, the transfection protocol requires 
temporal restrictions in order to be successful.  
A protocol was established for transfecting RAW 264.7 cells with these fluorescent 
biosensor plasmids using lipofectamine. This method was optimized to keep the transfection rate 
of the macrophages around 60-80%. Additional tests were performed to image transfected cells 
both live and fixed to coverslips with similar results. All biosensors tested, including GFP-PASS 
(sensing PA), GFP-LactC2 (sensing PS), GFP-2FYVE (sensing PI3P), GFP-P4M (sensing PI4P), 
and GFP-PHDx3 (sensing PI5P) were able to display fluorescent signal (Figure 32). The signal 
displayed by these transfected macrophages was not as obviously distinct as the signal seen 
previously in COS-7 cells. The small size of the macrophages and the lower cell density made 
imaging at high resolution more challenging. Several of the transfected macrophages, across all 
transfection groups, displayed a few common signal issues. Firstly, discrepancies in the type of 
signal produced by the same biosensor were observed depending on the time of imaging post-
transfection. Additionally, some cells appeared entirely fluorescent, potentially due to 
overexpression of the biosensor, and did not allow for any discrimination of localization patterns. 
Lastly, several cells appeared to be dead or dying and displayed highly fragmented signals. These 
signal issues were reiterated by time course imaging experiments performed by other members 
of the lab using these same biosensors. Moving forward, the frequency at which transfected cells 
display these types of signals should continue to be monitored. Advancing into M. tb infections 
of the transfected macrophages will require further optimization of RAW 264.7 cell density, 
appropriate MOI, and ideal imaging time post-infection. Overall, the establishment of these 
biosensor expressing cells positions this work to begin exploring EspD’s phospholipid binding 




Figure 32: RAW 264.7 murine macrophage cells transfected with (a) GFP-PASS plasmid, 
sensing PA (b) GFP-LactC2 plasmid, sensing PS (c) GFP-2FYVE plasmid, sensing PI3P (d) 
GFP-P4M plasmid, sensing PI4P (e) GFP-PHDx3 plasmid, sensing PI5P. Live cell imaging was 
performed 16 h post-transfection on the Leica TCS SP8 confocal microscope using Leica 
Application Suite X software version 3.4.2.18368. Magnification was achieved using 63x oil 




 In this work, we sought to better characterize the M. tb secreted protein, EspD. 
Unpublished work on this protein demonstrated that secreted EspD may contribute to M. tb 
replication in mice (Figure 6). Additionally, unpublished work uncovered that purified 
recombinant EspD may be capable of binding to eukaryotic phospholipids (Figure 8). This led to 
the hypothesis that secreted EspD interacts with eukaryotic phospholipids and disrupts host-cell 
processes to potentiate ESX-1 mediated M. tb virulence. We have attempted to address this 
through the characterization of M. tb strains that express variants of EspD, analyzing these strains 
in their interactions with macrophages, and studying purified recombinant EspD protein. 
 
5.1. Characterization of M. tb espA::Tn strains expressing EspD variants 
There is very little known about EspD, its structure or its function. Analysis of EspD’s 
protein sequence did not reveal any known functional domains or previously characterized 
structural regions. Therefore, to begin studying this protein, mutations were made to the EspD 
protein expressed in M. tb in the hopes of identifying new phenotypes. The mutations made to 
EspD were targeted to highly conserved areas of the protein on residues with basic, positively 
charged side chains (Figure 9). These residues may be involved in the binding to eukaryotic 
phospholipids observed in the unpublished data (Figure 8). The basic side chains could form 
favorable electrostatic interactions with the negatively charged head group of the phospholipid. 
Mutating these basic residues resulted in the construction of five new strains of M. tb which 
express EspD with alanine substitutions of arginine or lysine residues.  
In addition to the newly constructed strains, several strains for which secretion profiles 
were previously published were used in this study. The secretion profiles for the published strains 
were confirmed here, identifying M. tb espA::Tn pMDespACDW19R as a key strain, which can be 
utilized as a negative control for EspD secretion without interrupting the secretion of other ESX-
1 proteins. The newly constructed strains, with EspD mutated on conserved basic residues, did 
not establish any new growth or secretion phenotypes as all new strains demonstrated the ability 
to secrete EsxA and their mutated EspD proteins (Figures 10 & 11). Interestingly, the level of 
EspD mutant secretion appeared to differ subtly between these strains (Figure 11). As EspD is 
secreted at quite low concentrations relative to other secreted proteins, this variability will be 
interesting to interrogate more deeply in the future. These strains will be utilized in monitoring 
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phospholipid localization and signal changes during M. tb infections of macrophages expressing 
fluorescent phospholipid biosensors. However, for further investigation into the impact to 
cytotoxicity and inflammation, M. tb espA::Tn pMDespACDR92A was selected for further 
characterization here as this strain was found to consistently secrete a similar level of EspDR92A 
to that of M. tb espA::Tn pMDespACDWT. Additionally, M. tb espA::Tn pMDespACDW19R and 
the control strains: M. tb espA::Tn pMD31, M. tb espA::Tn pMDespACDWT, and M. tb espA::Tn 
pMDespACDSTOP were used for these experiments.  
These selected M. tb strains were evaluated for their cytotoxic effect on THP-1 human 
macrophages through PrestoBlue and LDH assays. Firstly, an effective protocol was developed 
for maintaining, differentiating, and infecting THP-1 cells (Figures 12 &13). These cells were 
then infected with M. tb at an MOI of 5 for three days at which time the infection supernatants 
were evaluated for the presence of LDH, an enzyme released from dying cells as the plasma 
membrane is damaged. The LDH assay was found to require further optimization as several 
values for percent relative cytotoxicity were calculated to be outside of the 0-100% range (Figure 
15). Additionally, LDH analysis of M. tb espA::Tn pMDespACDR92A infection supernatants 
displayed unrealistically low values for percent cytotoxicity. As M. tb espA::Tn pMD-
espACDR92A has a similar secretion profile to M. tb espA::Tn pMDespACDWT, the similar 
cytotoxicity observed with these strains through PrestoBlue analysis appears more consistent 
with current understandings of this strain. However, the trend observed for the remaining selected 
strains from the LDH experiment corresponded with what was observed with PresoBlue analysis 
(Table 4). The infected THP-1 cells were monitored for their ability to respirate through the 
conversion of PrestoBlue into a fluorescent product. The PrestoBlue results demonstrated that M. 
tb espA::Tn pMDespACDW19R, a strain unable to secrete EspD alone, appeared to have a similar 
level of cytotoxicity in THP-1 cells to a strain unable to secrete several ESX-1 proteins, M. tb 
espA::Tn pMDespACDSTOP (Figure 14). Both of these strains appeared less cytotoxic to THP-1 
cells than M. tb espA::Tn pMDespACDWT (Figure 14). These differences were not statistically 
significant; however, this trend was consistent across three independent experiments. Taken 
together with the evidence of M. tb espA::Tn pMDespACDW19R causing a reduced bacterial load 
in infected mice compared to M. tb espA::Tn pMDespACDWT, it appears that secreted EspD 
indeed has an impact on virulence during M. tb infections (Figures 6, 14, &15). 
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There are several pathways involved in eukaryotic cell death during M. tb infections 
(Zhang et al., 2021). The subtle phenotype observed with the PrestoBlue cytotoxicity experiments 
between the selected M. tb strains may indicate that overall cell death is not the best measurement 
for the impact of secreted EspD. This assay is only representative of the overall cell death 
observed after three days of infection. Continued investigation into these phenotypes could 
benefit from performing infections for 24 h or 48 h with higher MOIs. Perhaps the phenotype is 
more evident during very early stages of infection, as was observed with investigations into the 
pro-inflammatory response induced in these infected THP-1 cells.  
 
5.2. Analysis of the impact of secreted EspD during M. tb infections of macrophages 
Secreted EspD appears to contribute to the virulence of M. tb as evidenced by the reduced 
cytotoxicity in THP-1 cells infected with M. tb espA::Tn pMDespACDW19R compared to M. tb 
espA::Tn pMDespACDWT. To further explore the role of secreted EspD, the selected M. tb strains 
were used to infect THP-1 cells at an MOI of 10 for 24 h to observe differences in cytokine 
production. Interestingly, the production of IL1β and TNFα was largely reduced in the case of 
THP-1 cell infections with M. tb espA::Tn pMDespACDW19R compared to M. tb espA::Tn 
pMDespACDWT (Figure 16). This suggests that secreted EspD is involved in the production of 
pro-inflammatory cytokines. M. tb espA::Tn pMDespACDR92A and M. tb espA::Tn pMD-
espACDWT induced similar levels of IL1β and TNFα production in THP-1 cells, which is 
expected due to their similar secretion profiles (Figure 16). However, an interesting phenotype 
was uncovered for M. tb espA::Tn pMDespACDSTOP. This strain does not express EspD, which 
leads to the loss of secretion of EspA, EspC, EsxA, and EsxB. M. tb espA::Tn pMDespACDSTOP 
was shown to consistently display a lower cytotoxic effect towards THP-1 cells relative to M. tb 
espA::Tn pMDespACDWT (Figures 14 & 15). While observing the induction of IL1β and TNFα, 
it was found that M. tb espA::Tn pMDespACDSTOP induced an increased amount of pro-
inflammatory cytokine compared to M. tb espA::Tn pMDespACDWT (Figure 16). Previously, it 
was thought that ESX-1 mediated cytotoxicity in macrophages correlates with an increased pro-
inflammatory response in host-cells (Chen et al., 2013a). Here, the M. tb espA::Tn 
pMDespACDSTOP strain provides evidence that ESX-1 dependent cell death does not necessarily 
correspond with increased production of pro-inflammatory cytokines.  
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Having discovered that secreted EspD is somehow involved in the pro-inflammatory 
response in M. tb infected macrophages, further investigation was done into the host-cell 
pathways involved. As the EspD protein has demonstrated an ability to bind eukaryotic 
phospholipids (Figures 8, 16, & 27), it could be speculated that this binding may be involved in 
the secreted protein’s role in the host-cell’s inflammatory response. PI4P is a very abundant 
phospholipid in eukaryotic cells and is a key component of the Golgi apparatus (Del Campo et 
al., 2014). This phospholipid is involved in membrane trafficking at the Golgi as well as being 
the scaffold for the formation of the NLRP3 inflammasome complex (Chen and Chen, 2018; De 
Matteis et al., 2013). NLRP3 is recruited to the Golgi and binds to PI4P in order to further bind 
the adapter protein, ASC, and caspase-1 to form the NLRP3 inflammasome complex (Broz and 
Dixit, 2016; Rathinam and Fitzgerald, 2016). If secreted EspD is able to target PI4P during an 
infection, it is possible that this binding could induce or stabilize the formation of the NLRP3 
inflammasome (Figure 32). The presence of secreted EspD may thereby contribute to the 
activation of caspase-1 and lead to the cleavage of Pro-IL1β into IL1β.  
 
 
Figure 33: Potential inflammatory pathways that could be impacted by the presence of secreted 
EspD produced by M. tb during macrophage infection. Figure adapted from Rathinam and 




The presence of secreted EspD during M. tb infections could also influence NF-κB 
signaling. NF-κB is an important transcription factor involved in several aspects of the 
inflammatory response and its signaling pathway is highly interconnected with that of TNFα 
(Hayden and Ghosh, 2014; Liu et al., 2017b). Additionally, NF-κB has been shown to be 
influenced by PI4P treatment. Macrophages infected with mycobacteria have exhibited enhanced 
NF-κB activation when treated with exogenous PI4P (Gutierrez et al., 2009). Here, we show that 
secreted EspD contributes to the production of TNFα (Figure 16b) and that EspD appears to bind 
PI4P (Figures 8, 16, & 27). Therefore, it is of interest to monitor NF-κB and its phosphorylation 
in addition to the activation of the NLRP3 inflammasome in M. tb infected macrophages. To 
begin exploring whether changes in these host-cell responses are occurring, we observed the 
presence of several proteins in THP-1 cell lysates after infection with the selected M. tb strains. 
Infections were performed at an MOI of 10 for 24 h and lysates were harvested for analysis 
through immunoblot to observe NLRP3, cleaved caspase-1, and pNF-κB. Results did not 
demonstrate any difference between lysates of THP-1 cells infected with M. tb espA::Tn 
pMDespACDW19R and M. tb espA::Tn pMDespACDWT (Figures 17 & 18). Similarly, the infected 
lysates did not differ from the uninfected lysates for the presence of any of the targeted proteins. 
It is likely that the signals observed for these proteins represent their basal levels within the cell 
and are not indicative of any activation of the inflammatory pathways (Figure 17 & 18).  
Lysates used in these Western blot experiments were harvested at 24 h post-infection. 
This single time point did not demonstrate any differences between M. tb espA::Tn 
pMDespACDWT infected and uninfected cells and therefore could not identify any differences 
with the EspD secretion control strain, M. tb espA::Tn pMDespACDW19R. A time course, 
harvesting infected cell lysates over several shorter time periods would be the next necessary step 
for investigating this phenotype. Additionally, due to the inability to detect strong signal from 
cleaved caspase-1 across several protein concentrations analyzed through Western blot, tests 
should be performed to ensure this antibody is functional. All antibodies used in these 
experiments were obtained commercially and were prepared as recommended by the 
manufacturer, however, attempts should be made to optimize antibody signal, especially in the 
case of cleaved caspase-1 and pNF-κB with the use of titrations, positive control samples, and 
varying primary antibody concentrations.  
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In addition to investigating changes in the inflammatory response, we wanted to examine 
if there are changes in phospholipid localization of macrophages in response to infections with 
M. tb strains expressing variant EspD proteins. EspD’s potential to bind eukaryotic phospholipids 
during infection could contribute to M. tb’s ability to hijack and manipulate host-defense 
mechanisms. Many pathogenic bacteria, including M. tb, are known to target phospholipids and 
therefore interfere with their functions in cell-signaling, maintenance of cytoskeletal dynamics, 
membrane composition, and more (Walpole et al., 2018). Monitoring changes to the localization 
patterns of several key phospholipids during infections with these M. tb strains could allow for 
visual evidence of the role EspD is playing. To observe these changes a collection of fluorescent 
biosensor plasmids, encoding phospholipid-specific probes linked to GFP or RFP, was made. 
These biosensors were tested in both COS-7 and RAW 264.7 cell lines and were found to be 
functional. This work established a methodology for using these phospholipid biosensors and 
will enable future infections of these cells to observe strain to strain differences.  
 
5.3. Purification and analysis of recombinant EspD protein from E. coli 
Purification trials were performed on recombinant EspD from E. coli for the purposes of 
further evaluating the structure and function of EspD. Ideally, purification would be performed 
under non-denaturing conditions. This allows for a higher quality protein sample as the protein 
remains properly folded throughout the purification. Protein refolding can occur for samples 
purified under denaturing conditions; however, this is more likely to produce unfolded or 
misfolded protein, which can yield inaccurate biophysical and biochemical information. Here, a 
proposed protocol for purification of recombinant EspD from E. coli under non-denaturing 
conditions was created. The trials attempted for non-denaturing EspD purification were met with 
consistent aggregation issues despite testing numerous buffer conditions. Ultimately, a major 
source of the aggregation was found to be the dried Nickel-IDA silica-based resin originally used 
for His-tag purification. Replacing this resin, which had been previously used in the small-scale 
purifications performed for EspD in the unpublished data, allowed for EspD purification to 
proceed and allowed for enhanced stability of the protein in solution. Further optimization of the 
later purification steps to enhance purity may be required moving forward. Once successful 
purification of EspD under non-denaturing conditions is completed it will be of key importance 
to identify and purify variants of EspD to begin to investigate the key residues of this protein. 
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Sequence analysis of EspD indicates that there may be an intrinsically unfolded region located 
on the N-terminal portion of the protein. Truncations performed in this region may help to gain 
insights into the structure of EspD’s C-terminal region and could provide information regarding 
how this disordered region may contribute to EspD’s function. Additionally, large scale non-
denatured purifications of EspD will allow for biophysical analysis of the protein through CD 
and DLS to gather more insight into the structure and oligomerization of the protein. Furthermore, 
this protein can be used to confirm the phospholipid binding analyses that were performed here 
using EspD samples purified under denaturing conditions. 
Although not ideal or preferred, a relatively pure sample of recombinant EspD was 
obtained under denaturing conditions and used to confirm the phospholipid binding phenotype 
demonstrated in the unpublished data (Figure 8). Here, we were able to repeat this phenotype, 
showing that recombinant EspD was able to bind to PA, PI3P, PI4P, and PI5P using phospholipid 
embedded membranes (Figure 26). Similarly, recombinant EspD demonstrated binding to PA 
and PI4P during pulldowns with phospholipid coated beads (Figure 27). In the case of both the 
phospholipid embedded membranes and the phospholipid coated beads EspD demonstrated 
strong binding to PI4P. To further confirm this binding to PI4P, pulldown experiments were 
performed using M. tb expressed EspD. Initial pulldowns were performed using lysates of M. tb 
espA::Tn pMDespACDWT and M. tb espA::Tn pMDespACDSTOP. Cell lysates contain a much 
higher relative concentration of EspD and were able to serve as a proof-of-concept to determine 
if EspD could be pulled down from a mixture of proteins using this method. Indeed, EspD protein 
was able to be pulled down by the PI4P-coated beads from the M. tb espA::Tn pMDespACDWT 
cell lysate (Figure 28). Despite the need for stronger washing in this experiment to remove all 
non-specific binding to the control beads, the stronger signal from the PI4P-coated beads seems 
to imply EspD and PI4P are binding. Lastly, to observe PI4P binding to secreted EspD, culture 
filtrate samples of M. tb espA::Tn pMDespACDWT and M. tb espA::Tn pMDespACDSTOP were 
used in a similar pulldown. Again, EspD can be visualized in the PI4P-coated bead pulldown 
from M. tb espA::Tn pMDespACDWT (Figure 29). Optimization of this methodology may be 
necessary to amplify the faint signal. It is likely that the high concentration of other secreted 
proteins in the sample causes interference with the binding or with the Western blot analysis itself. 
Overall, EspD consistently appears to demonstrate phospholipid binding. The recombinant EspD 
protein produced under non-denaturing conditions from the unpublished data (Figure 8), the 
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recombinant EspD protein produced under denaturing conditions (Figures 26 & 27), and the M. 
tb secreted EspD used in pulldowns (Figure 29) were all able to provide evidence of EspD’s 
ability to bind eukaryotic phospholipids, especially PI4P.  
 
5.4. Conclusions 
 This work has established a better understanding of the role EspD plays during M. tb 
infections of macrophages. Several new strains of M. tb expressing single point variants of EspD 
were constructed. These strains were found to possess no growth defects and were all capable of 
secreting the ESX-1 proteins, EsxA and EspD. Secretion profiles of several previously published 
variant M. tb strains were additionally confirmed here (Chen et al., 2012). A strain incapable of 
secreting EspD alone, M. tb espA::Tn pMDespACDW19R, appeared to be less cytotoxic to THP-1 
macrophages and induced a significantly lower concentration of pro-inflammatory cytokine 
compared to M. tb espA::Tn pMDespACDWT. This indicates that secreted EspD appears to be 
involved in the virulence of M. tb during infections of macrophages and contributes to the pro-
inflammatory response of the host-cells. This work also demonstrated that both recombinantly 
produced EspD protein and M. tb secreted EspD protein are capable of binding eukaryotic 
phospholipids, including PI4P. Overall, this work provides a foundation for further investigation 
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